[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1422
1. Sholl LM, Yeap BY, Iafrate AJ, Holmes-Tisch AJ, Chou YP, Wu MT, Goan YG, Su L, Benedettini E, Yu J, Loda M, Jänne PA, Christiani DC, Chirieac LR: Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokers. Cancer Res; 2009 Nov 1;69(21):8341-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokers.
  • In a subset of lung adenocarcinomas, the epidermal growth factor receptor (EGFR) is activated by kinase domain mutations and/or gene amplification, but the interaction between the two types of abnormalities is complex and unclear.
  • For this study, we selected 99 consecutive never-smoking women of East Asian origin with lung adenocarcinomas that were characterized by histologic subtype.
  • Lung adenocarcinomas with EGFR amplification had significantly more EGFR exon 19 deletion mutations than adenocarcinomas with disomy, and low and high polysomy (100% versus 54%, P = 0.009).
  • EGFR amplification occurred invariably on the mutated and not the wild-type allele (median mutated/wild-type ratios 14.0 versus 0.33, P = 0.003), was associated with solid histology (P = 0.008), and advanced clinical stage (P = 0.009).
  • EGFR amplification was focally distributed in lung cancer specimens, mostly in regions with solid histology.
  • Patients with EGFR amplification had a significantly worse outcome in univariate analysis (median disease-free survival, 16 versus 31 months, P = 0.01) and when adjusted for stage (P = 0.027).
  • Lung adenocarcinomas with EGFR amplification have a unique association with exon 19 deletion mutations and show distinct clinicopathologic features associated with a significantly worsened prognosis.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):839-44 [16467097.001]
  • [Cites] Clin Cancer Res. 2009 May 1;15(9):3023-8 [19366827.001]
  • [Cites] Cancer Cell. 2006 Jun;9(6):485-95 [16730237.001]
  • [Cites] Clin Cancer Res. 2006 Jul 1;12(13):3908-14 [16818686.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):5034-42 [17075123.001]
  • [Cites] Nat Rev Cancer. 2007 Mar;7(3):169-81 [17318210.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):2046-53 [17332333.001]
  • [Cites] J Clin Oncol. 2007 Jun 1;25(16):2248-55 [17538169.001]
  • [Cites] Mod Pathol. 2007 Oct;20(10):1028-35 [17673923.001]
  • [Cites] J Thorac Oncol. 2008 Apr;3(4):340-7 [18379350.001]
  • [Cites] Cancer Res. 2008 Apr 1;68(7):2106-11 [18381415.001]
  • [Cites] J Mol Diagn. 2008 May;10(3):242-8 [18403609.001]
  • [Cites] Am J Surg Pathol. 2008 Jun;32(6):810-27 [18391747.001]
  • [Cites] N Engl J Med. 2008 Sep 25;359(13):1367-80 [18815398.001]
  • [Cites] Nature. 2008 Oct 23;455(7216):1069-75 [18948947.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37 [11252954.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] Science. 2004 Aug 20;305(5687):1163-7 [15284455.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11 [15329413.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8195-203 [15623594.001]
  • [Cites] Cancer Res. 2005 Jan 1;65(1):226-35 [15665299.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1167-73 [15709185.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 2;97(5):339-46 [15741570.001]
  • [Cites] J Natl Cancer Inst. 2005 May 4;97(9):643-55 [15870435.001]
  • [Cites] J Natl Cancer Inst. 2005 Aug 17;97(16):1185-94 [16106023.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):6838-45 [15998906.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):6829-37 [15998907.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):751-8 [16467085.001]
  • [Cites] Cancer Prev Res (Phila). 2008 Aug;1(3):192-200 [19138956.001]
  • [Cites] PLoS One. 2009;4(2):e4576 [19238210.001]
  • [Cites] Am J Clin Pathol. 2006 Jun;125(6):860-5 [16690485.001]
  • (PMID = 19826035.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P20 CA090578; United States / NCI NIH HHS / CA / CA092824; United States / NCI NIH HHS / CA / CA074386; United States / NCI NIH HHS / CA / CA090578-01A10003; United States / NCI NIH HHS / CA / P50 CA090578; United States / NCI NIH HHS / CA / R0I CA114465; United States / NCI NIH HHS / CA / R01 CA114465; United States / NCI NIH HHS / CA / P20 CA090578-01A10003
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.6.5.2 / ras Proteins
  • [Other-IDs] NLM/ NIHMS143923; NLM/ PMC2783286
  •  go-up   go-down


2. Liao YD, Long QH, Zhou S, Zhao JP, Huang Q, Fu XN: [Expression of PKB protein in human squamous-cell carcinoma and adenocarcinoma of lung]. Zhonghua Zhong Liu Za Zhi; 2005 Mar;27(3):156-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of PKB protein in human squamous-cell carcinoma and adenocarcinoma of lung].
  • OBJECTIVE: To investigate the expression of protein kinase B (PKB) in human-squamous cell carcinoma (SCC) and adenocarcinoma of lung (ADC) and in benign lung tissues (BD, lung tissues adjacent to cancer or from patients with benign lung diseases), and its association to clinicopathological characteristics.
  • METHODS: The PKB expression in 41 specimens from patients with SCC (26 cases) and ADC (15 cases) and in 12 specimens from patients with benign lung diseases (BD) were investigated by immunohistochemistry and Western blot analysis.
  • RESULTS: PKB in benign lung tissues was usually weakly stained and scattered in distribution.
  • It was remarkably increased in lung cancer compared to benign lung tissue.
  • PKB expression was significantly stronger in lung cancer patients in advanced stages (stage III or IV) or with poor differentiation, than those in early stages (stage I or II) or with moderate or well differentiation.
  • CONCLUSION: PKB protein is over-expressed in human squamous-cell carcinoma and adenocarcinoma of lung.
  • [MeSH-major] Adenocarcinoma / metabolism. Carcinoma, Squamous Cell / metabolism. Lung Neoplasms / metabolism. Proto-Oncogene Proteins c-akt / metabolism
  • [MeSH-minor] Adult. Aged. Female. Humans. Lung / metabolism. Lymph Nodes / pathology. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Plasma Cell Granuloma, Pulmonary / metabolism


3. Lee HJ, Choe G, Jheon S, Sung SW, Lee CT, Chung JH: CD24, a novel cancer biomarker, predicting disease-free survival of non-small cell lung carcinomas: a retrospective study of prognostic factor analysis from the viewpoint of forthcoming (seventh) new TNM classification. J Thorac Oncol; 2010 May;5(5):649-57
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD24, a novel cancer biomarker, predicting disease-free survival of non-small cell lung carcinomas: a retrospective study of prognostic factor analysis from the viewpoint of forthcoming (seventh) new TNM classification.
  • However, the importance of the CD24 in non-small cell lung carcinomas (NSCLCs) has not been elucidated well.
  • RESULTS: CD24-high expression was demonstrated in 87 of 267 (33%) and was associated with adenocarcinoma (ADC) histology than in squamous cell carcinoma histology (64 of 165 [39%] vs. 20 of 88 [23%]; p = 0.023).
  • CD24-high expression had a tendency to correlate with new pathologic stage (p-stage) (p = 0.089) rather than old p-stage (p = 0.253).
  • Performance status and new p-stage, regardless of the tumor histology, were identified as consistent independent prognostic factors of disease progression and cancer-related death.
  • Performance status and new p-stage, to a lesser extent, age correlated with progression-free survival and cancer-specific survival, regardless of tumor histology.
  • [MeSH-major] Adenocarcinoma / metabolism. Antigens, CD24 / metabolism. Biomarkers, Tumor / metabolism. Carcinoma, Non-Small-Cell Lung / metabolism. Carcinoma, Squamous Cell / metabolism. Lung Neoplasms / metabolism

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Biomark Med. 2010 Aug;4(4):495 [20701438.001]
  • (PMID = 20354454.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD24; 0 / Biomarkers, Tumor; 0 / CD24 protein, human
  •  go-up   go-down


Advertisement
4. Novaes FT, Cataneo DC, Ruiz Junior RL, Defaveri J, Michelin OC, Cataneo AJ: Lung cancer: histology, staging, treatment and survival. J Bras Pneumol; 2008 Aug;34(8):595-600
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung cancer: histology, staging, treatment and survival.
  • OBJECTIVE: To analyze principal histological types of lung cancer, as well as the staging, treatment and survival of lung cancer patients.
  • RESULTS: From January of 2000 to January of 2006, 240 patients with lung cancer, most (64%) of whom were male, were treated.
  • The most common histological type was squamous cell carcinoma (37.5%), followed by adenocarcinoma (30%), neuroendocrine carcinoma (19.6%) and large cell carcinoma (6.6%).
  • Concerning staging, 34.4% presented stage IV at the time of diagnosis, 20.6% presented stage IIIB, 16.8% presented stage IIIA, and the remaining 28.2% were classified as stage I or II.
  • Five-year survival was 65% for those in stage I and 25% for those in the remaining stages.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Squamous Cell / pathology. Lung Neoplasms / pathology

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18797744.001).
  • [ISSN] 1806-3756
  • [Journal-full-title] Jornal brasileiro de pneumologia : publicaça̋o oficial da Sociedade Brasileira de Pneumologia e Tisilogia
  • [ISO-abbreviation] J Bras Pneumol
  • [Language] eng; por
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


5. Nishimura T, Nomura M, Tojo H, Hamasaki H, Fukuda T, Fujii K, Mikami S, Bando Y, Kato H: Proteomic analysis of laser-microdissected paraffin-embedded tissues: (2) MRM assay for stage-related proteins upon non-metastatic lung adenocarcinoma. J Proteomics; 2010 Apr 18;73(6):1100-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic analysis of laser-microdissected paraffin-embedded tissues: (2) MRM assay for stage-related proteins upon non-metastatic lung adenocarcinoma.
  • A preceding paper suggested 81 candidates of stage-specifically expressed proteins for either stage IA or IIIA by global shotgun proteomics and spectral counting.
  • The multiple-reaction monitoring (MRM) quantitative analysis suggested that napsin-A and anterior gradient protein 2 homolog (hAG-2) out of the 6 candidates would be useful for determining stage IA or IIIA and are related to metastasis.
  • In the study we noted that stage IIIA patients with better outcome showed napsin-A profiles similar to that of stage IA patients.
  • We therefore examined 14 additional patients for analysis, which contained the IA-stage patients of poorer outcome and the IIIA-stage patients of better outcome.
  • The MRM analysis of napsin-A for all patients suggests that napsin-A contents correlate with better outcome in stage IA.
  • [MeSH-major] Adenocarcinoma / diagnosis. Lung Neoplasms / diagnosis. Microdissection. Proteomics / methods

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier B.V. All rights reserved.
  • (PMID = 19944198.001).
  • [ISSN] 1876-7737
  • [Journal-full-title] Journal of proteomics
  • [ISO-abbreviation] J Proteomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Proteome; EC 3.4.23.- / Aspartic Acid Endopeptidases; EC 3.4.23.- / NAPSA protein, human
  •  go-up   go-down


6. Miller AA, Wang XF, Gu L, Hoffman P, Khatri J, Dunphy F, Edelman MJ, Bolger M, Vokes EE, Green MR, Cancer and Leukemia Group B (CALGB): Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303). J Thorac Oncol; 2008 Oct;3(10):1159-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303).
  • INTRODUCTION: We investigated dose-dense docetaxel and cisplatin in patients with measurable non-small cell lung cancer in a randomized phase II study without [A] or with [B] a putative chemoprotective agent, BNP7787.
  • PATIENTS AND METHODS: Chemotherapy-naive patients with stage IIIB (effusion) or IV, performance status 0 to 1, and adequate organ function were eligible.
  • Its further investigation in the curative setting in non-small cell lung cancer should be considered.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Erythropoietin / analogs & derivatives. Granulocyte Colony-Stimulating Factor / therapeutic use. Lung Neoplasms / drug therapy. Mesna / analogs & derivatives
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Adenocarcinoma, Bronchiolo-Alveolar / drug therapy. Adenocarcinoma, Bronchiolo-Alveolar / secondary. Adult. Aged. Anemia / drug therapy. Brain Neoplasms / drug therapy. Brain Neoplasms / secondary. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / secondary. Cisplatin / administration & dosage. Darbepoetin alfa. Dose-Response Relationship, Drug. Drug Therapy, Combination. Feasibility Studies. Female. Filgrastim. Hematinics / therapeutic use. Humans. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging. Neutropenia / drug therapy. Prognosis. Recombinant Proteins. Survival Rate. Taxoids / administration & dosage

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. Filgrastim .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DARBEPOETIN ALFA .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18827613.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA03927; United States / NCI NIH HHS / CA / CA114558-02; United States / NCI NIH HHS / CA / CA21060; United States / NCI NIH HHS / CA / CA31946; United States / NCI NIH HHS / CA / CA31983; United States / NCI NIH HHS / CA / CA33601; United States / NCI NIH HHS / CA / CA35113; United States / NCI NIH HHS / CA / CA35421; United States / NCI NIH HHS / CA / CA37447; United States / NCI NIH HHS / CA / CA41287; United States / NCI NIH HHS / CA / CA45389; United States / NCI NIH HHS / CA / CA45418; United States / NCI NIH HHS / CA / CA45564; United States / NCI NIH HHS / CA / CA45808; United States / NCI NIH HHS / CA / CA47559; United States / NCI NIH HHS / CA / CA47577; United States / NCI NIH HHS / CA / CA47642; United States / NCI NIH HHS / CA / CA74811; United States / NCI NIH HHS / CA / CA77298; United States / NCI NIH HHS / CA / CA77440
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hematinics; 0 / Recombinant Proteins; 0 / Taxoids; 11096-26-7 / Erythropoietin; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 15H5577CQD / docetaxel; 15UQ94PT4P / Darbepoetin alfa; 3A58010674 / pegfilgrastim; 45127-11-5 / 2,2'-dithiodiethanesulfonic acid; NR7O1405Q9 / Mesna; PVI5M0M1GW / Filgrastim; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


7. Imaizumi M, Study Group of Adjuvant Chemotherapy for Lung Cancer (Chubu, Japan): Postoperative adjuvant cisplatin, vindesine, plus uracil-tegafur chemotherapy increased survival of patients with completely resected p-stage I non-small cell lung cancer. Lung Cancer; 2005 Jul;49(1):85-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative adjuvant cisplatin, vindesine, plus uracil-tegafur chemotherapy increased survival of patients with completely resected p-stage I non-small cell lung cancer.
  • PURPOSE: To evaluate the efficacy of postoperative adjuvant chemotherapy for completely resected p-stage I non-small cell lung cancer (NSCLC).
  • MATERIALS AND METHODS: Patients who underwent complete resection with lymph node dissection for p-stage I NSCLC (T1N0, T2N0, adenocarcinoma or squamous cell carcinoma, were eligible.
  • CONCLUSION: Postoperative PVU chemotherapy is effective for Japanese patients with completely resected p-stage I NSCLC.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / surgery. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / surgery. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / surgery. Lung Neoplasms / drug therapy. Lung Neoplasms / surgery

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. VINDESINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15949594.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] Ireland
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; Q20Q21Q62J / Cisplatin; RSA8KO39WH / Vindesine
  •  go-up   go-down


8. Barlési F, Nanni-Metellus I, Breen D, Fina F, Astoul P, Martin PM: Non-small cell lung cancer-smokers or non-smokers, does it matter? Lung Cancer; 2009 Mar;63(3):430-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-small cell lung cancer-smokers or non-smokers, does it matter?
  • We illustrate the difficulties faced by clinicians with the case of a 56-year-old man with stage IV lung adenocarcinoma and a smoking history of 30-pack-year.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. DNA, Neoplasm / genetics. Lung Neoplasms / genetics. Mutation. Receptor, Epidermal Growth Factor / genetics


9. Pelosi G, Del Curto B, Dell'Orto P, Pasini F, Veronesi G, Spaggiari L, Maisonneuve P, Iannucci A, Terzi A, Lonardoni A, Viale G: Lack of prognostic implications of HER-2/neu abnormalities in 345 stage I non-small cell carcinomas (NSCLC) and 207 stage I-III neuroendocrine tumours (NET) of the lung. Int J Cancer; 2005 Jan 1;113(1):101-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lack of prognostic implications of HER-2/neu abnormalities in 345 stage I non-small cell carcinomas (NSCLC) and 207 stage I-III neuroendocrine tumours (NET) of the lung.
  • Irrespective of protein overexpression, HER-2/neu gene amplification is rare in lung cancer and studies on its prevalence and clinicopathological implications in early stage non-small cell lung cancer (NCSLC) and neuroendocrine tumours (NET) of the lung are lacking.
  • We evaluated HER-2/neu abnormalities in 345 Stage I NSCLC and 207 Stage I-III NET of the lung of all the diverse histological types, by using immunohistochemistry and fluorescent in situ hybridization in selected cases.
  • HER-2/neu gene amplification and protein overexpression are not closely correlated in lung carcinomas and do not bear any prognostic implication.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. Chromosome Aberrations. Gene Amplification. Genes, erbB-2. Lung Neoplasms / genetics. Receptor, ErbB-2 / metabolism
  • [MeSH-minor] Adenocarcinoma / genetics. Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Neuroendocrine / genetics. Carcinoma, Squamous Cell / genetics. Chromosomes, Human, Pair 17. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Prognosis. Retrospective Studies. Up-Regulation

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15386424.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


10. Que CL, Zhang PJ, Wang WH, He B, Yin HF, Wang RG: [An analysis of the clinical and radiological features of bronchioloalveolar carcinoma]. Zhonghua Jie He He Hu Xi Za Zhi; 2006 Oct;29(10):662-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Data of 1 050 inpatients of lung cancer, including 50 cases of pathology-proven bronchioloalveolar carcinoma, diagnosed in our hospital between 1993 and 2003, were retrospectively reviewed.
  • Twenty-four patients sought medical attention because of abnormal chest X-rays, most of which were of nodular type at the early stage.
  • CONCLUSIONS: Bronchioloalveolar carcinoma accounted for 4.76% of lung carcinoma in our series, with a female predominance.
  • High prevalence of asymptomatic patients at presentation and unusual long course should prompt regular chest X-ray examination.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / radiography. Lung Neoplasms / radiography. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17129492.001).
  • [ISSN] 1001-0939
  • [Journal-full-title] Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  • [ISO-abbreviation] Zhonghua Jie He He Hu Xi Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


11. Carpenter B, McKay M, Dundas SR, Lawrie LC, Telfer C, Murray GI: Heterogeneous nuclear ribonucleoprotein K is over expressed, aberrantly localised and is associated with poor prognosis in colorectal cancer. Br J Cancer; 2006 Oct 9;95(7):921-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There were significant increases in both nuclear (P=0.007) and cytoplasmic (P=0.001) expression of hnRNP K in Dukes C tumours compared with early stage tumours.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / analysis. Colorectal Neoplasms / metabolism. Ribonucleoproteins / biosynthesis


12. Takeuchi T, Tomida S, Yatabe Y, Kosaka T, Osada H, Yanagisawa K, Mitsudomi T, Takahashi T: Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. J Clin Oncol; 2006 Apr 10;24(11):1679-88
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors.
  • PURPOSE: This study was conducted to gain insight into the relationship between expression profiles and underlying genetic changes, which are known to be important for the pathogenesis of lung cancers.
  • METHODS: Expression profiles of 18,175 unique genes and three major targets for genetic changes, p53, epidermal growth factor receptor (EGFR), and K-ras, were investigated in 149 patients with non-small-cell lung cancer, including 90 patients with adenocarcinoma to determine their relationships with various clinicopathologic features and Gene Ontology (GO) terms.
  • Our GO term-based identifier of particular biologic processes, molecular functions, and cellular compartments clearly showed characteristic retention of normal peripheral lung features in TRU type, in sharp contrast to the significant association of non-TRU type with cell cycling and proliferation-related features.
  • While significantly higher frequency of EGFR mutation was observed in TRU type, we found that the presence of EGFR mutations was a significant predictor of shorter postoperative survival for TRU type, independent of disease stage.
  • CONCLUSION: This study has shed light on heterogeneity in lung cancers, especially in adenocarcinomas, by establishing a molecularly, genetically, and clinically relevant, expression profile-defined classification.
  • Future studies using independent patient cohorts are warranted to confirm the prognostic significance of EGFR mutations in TRU-type adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Epidermal Growth Factor / genetics. Genes, ras / genetics. Lung Neoplasms / genetics. Molecular Biology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16549822.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 62229-50-9 / Epidermal Growth Factor
  •  go-up   go-down


13. Nagata Y, Takayama K, Matsuo Y, Norihisa Y, Mizowaki T, Sakamoto T, Sakamoto M, Mitsumori M, Shibuya K, Araki N, Yano S, Hiraoka M: Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys; 2005 Dec 1;63(5):1427-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame.
  • PURPOSE: To evaluate the clinical outcomes of 48 Gy of three-dimensional stereotactic radiotherapy in four fractions for treating Stage I lung cancer using a stereotactic body frame.
  • Thirty-two patients had Stage IA lung cancer, and the other 13 had Stage IB lung cancer where tumor size was less than 4 cm in diameter.
  • Three-dimensional treatment planning using 6-10 noncoplanar beams was performed to maintain the target dose homogeneity and to decrease the irradiated lung volume >20 Gy.
  • For Stage IA lung cancer, the disease-free survival and overall survival rates after 1 and 3 years were 80% and 72%, and 92% and 83%, respectively, whereas for Stage IB lung cancer, the disease-free survival and overall survival rates were 92% and 71%, and 82% and 72%, respectively.
  • CONCLUSION: Forty-eight Gy of 3D stereotactic radiotherapy in 4 fractions using a stereotactic body frame is useful for the treatment of Stage I lung tumors.
  • [MeSH-major] Lung Neoplasms / radiotherapy. Radiotherapy, Conformal / methods
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Feasibility Studies. Female. Humans. Male. Middle Aged. Stereotaxic Techniques. Survival Rate

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16169670.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


14. Redente EF, Dwyer-Nield LD, Merrick DT, Raina K, Agarwal R, Pao W, Rice PL, Shroyer KR, Malkinson AM: Tumor progression stage and anatomical site regulate tumor-associated macrophage and bone marrow-derived monocyte polarization. Am J Pathol; 2010 Jun;176(6):2972-85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor progression stage and anatomical site regulate tumor-associated macrophage and bone marrow-derived monocyte polarization.
  • In late stage human lung adenocarcinoma, TAMs exhibited mixed M1 (classical; argI(low)iNOS(high)) and M2 (alternative; argI(high)iNOS(low)) polarization based on arginine metabolism.
  • In several murine cancer models including chemically and genetically-induced primary lung tumors, prostate tumors, colon xenografts, and lung metastases, TAMs expressed argI(high)iNOS(low) early during tumor formation; argI(low)iNOS(high) polarization also occurred during malignancy in some models.
  • In a chemically-induced lung tumor model, macrophages expressed argI(high)iNOS(low) within one week after carcinogen treatment, followed by similar polarization of bone marrow-derived monocytes (BDMCs) a few days later.
  • Indeed, in both conditional mutant Kras- and FGF10-driven models of lung cancer, mice expressing the transgene develop lung tumors that regress rapidly when the transgene is silenced.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2007 Jun 15;67(12):5708-16 [17575137.001]
  • [Cites] J Clin Invest. 2007 May;117(5):1155-66 [17476345.001]
  • [Cites] Cancer Res. 2007 Jul 1;67(13):6520-7 [17596594.001]
  • [Cites] J Immunol. 2008 Feb 15;180(4):2011-7 [18250403.001]
  • [Cites] Int J Cancer. 2009 Aug 15;125(4):887-93 [19431148.001]
  • [Cites] Cancer Lett. 2000 May 1;152(2):151-6 [10773406.001]
  • [Cites] J Immunol. 2000 Jun 15;164(12):6166-73 [10843666.001]
  • [Cites] Neoplasia. 1999 Jun;1(2):170-6 [10933052.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):1100-6 [11221839.001]
  • [Cites] Lancet. 2001 Feb 17;357(9255):539-45 [11229684.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2001 Apr;280(4):L705-15 [11238011.001]
  • [Cites] Exp Lung Res. 2001 Apr-May;27(3):197-216 [11293324.001]
  • [Cites] Lung Cancer. 2001 Jun;32(3):265-79 [11390008.001]
  • [Cites] Toxicology. 2001 Dec 1;169(1):1-15 [11696405.001]
  • [Cites] Genes Dev. 2001 Dec 15;15(24):3249-62 [11751631.001]
  • [Cites] Cancer Res. 2002 Feb 1;62(3):734-40 [11830527.001]
  • [Cites] Trends Immunol. 2002 Nov;23(11):549-55 [12401408.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):846-52 [12490957.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] Nat Rev Immunol. 2003 Jan;3(1):23-35 [12511873.001]
  • [Cites] Immunol Lett. 2003 Jan 22;85(2):173-80 [12527225.001]
  • [Cites] Immunity. 2003 Jul;19(1):71-82 [12871640.001]
  • [Cites] Cancer Lett. 2003 Aug 20;198(2):139-44 [12957351.001]
  • [Cites] Mol Carcinog. 2003 Nov;38(3):117-23 [14587096.001]
  • [Cites] Curr Opin Immunol. 2004 Apr;16(2):157-62 [15023407.001]
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2307-16 [15059877.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2004 Oct;287(4):L685-703 [15355860.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7022-9 [15466195.001]
  • [Cites] J Immunol. 1979 Apr;122(4):1587-91 [376720.001]
  • [Cites] J Immunol. 1979 Apr;122(4):1592-97 [376721.001]
  • [Cites] J Immunol. 1980 Mar;124(3):1050-3 [6987306.001]
  • [Cites] J Natl Cancer Inst. 1983 May;70(5):931-6 [6573537.001]
  • [Cites] J Immunol. 1992 Oct 15;149(8):2709-14 [1401910.001]
  • [Cites] Mol Endocrinol. 1994 Feb;8(2):230-9 [8170479.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3439-43 [7724580.001]
  • [Cites] Cancer Res. 1995 Sep 1;55(17):3847-53 [7641203.001]
  • [Cites] Am J Respir Cell Mol Biol. 1996 May;14(5):444-53 [8624249.001]
  • [Cites] J Exp Med. 1996 Apr 1;183(4):1323-9 [8666890.001]
  • [Cites] Int Immunol. 1996 Dec;8(12):1915-25 [8982776.001]
  • [Cites] Histochem J. 1997 May;29(5):393-9 [9184853.001]
  • [Cites] Cancer Res. 1997 Jul 15;57(14):2832-4 [9230183.001]
  • [Cites] Am J Physiol. 1998 Nov;275(5 Pt 1):E740-7 [9814991.001]
  • [Cites] J Immunol. 1999 Apr 15;162(8):4606-13 [10202000.001]
  • [Cites] Oncology. 1999;57(2):138-42 [10461061.001]
  • [Cites] J Immunol. 1999 Oct 1;163(7):3771-7 [10490974.001]
  • [Cites] Trends Immunol. 2004 Dec;25(12):677-86 [15530839.001]
  • [Cites] J Leukoc Biol. 2005 Mar;77(3):321-7 [15591125.001]
  • [Cites] Exp Lung Res. 2005 Jan-Feb;31(1):57-82 [15765919.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3044-8 [15833831.001]
  • [Cites] J Immunol. 2005 Jul 1;175(1):342-9 [15972667.001]
  • [Cites] J Immunol. 2006 Apr 15;176(8):5023-32 [16585599.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2006 Jun;290(6):L1260-6 [16443645.001]
  • [Cites] Cancer Lett. 2006 Sep 28;241(2):197-202 [16337739.001]
  • [Cites] J Clin Invest. 2006 Aug;116(8):2132-2141 [16862213.001]
  • [Cites] J Immunol. 2006 Nov 15;177(10):7303-11 [17082649.001]
  • [Cites] J Immunol. 2007 Feb 1;178(3):1357-62 [17237382.001]
  • [Cites] Am J Pathol. 2007 Feb;170(2):693-708 [17255336.001]
  • [Cites] J Clin Invest. 2007 May;117(5):1137-46 [17476343.001]
  • [Cites] Cancer Res. 2007 Jun 15;67(12):5976-82 [17575168.001]
  • (PMID = 20431028.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA058187; United States / NCI NIH HHS / CA / R01 CA113876; United States / PHS HHS / / NCI 033497; United States / NCI NIH HHS / CA / PA50CA058187; United States / NCI NIH HHS / CA / R01 CA121210; United States / NCI NIH HHS / CA / CA113876; United States / PHS HHS / / NCI 132552
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 207137-56-2 / Interleukin-4; 82115-62-6 / Interferon-gamma
  • [Other-IDs] NLM/ PMC2877857
  •  go-up   go-down


15. Kim S, Wu HG, Lee HP, Kang SB, Song YS, Park NH, Ha SW: Patterns of failure after postoperative radiation therapy for endometrial carcinoma. Cancer Res Treat; 2006;38(3):133-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All the patients were staged according to 1988 FIGO (International Federation of Gynecology and Obstetrics) staging system; 2 were stage IA, 23 were stage IB, 20 were stage IC, 4 were stage IIA, 5 were stage IIB, 9 were stage IIIA, 2 were stage IIIB and 18 were stage IIIC.
  • The histologic diagnoses were adenocarcinoma in seventy-four patients (89%).
  • RESULTS: Overall, 11 patients (13%) experienced disease relapse: 4 with initial stage I or II disease and 7 with initial stage III disease.
  • Among the 54 stage I or II patients, 1 (2%) relapsed in the pelvis only, 2 (4%) relapsed in the vagina and distant organs, and 1 (2%) relapsed in the paraaortic lymph nodes (PANs).
  • Among the 29 stage III patients, 1 (3%) relapsed in the vagina.
  • The most common sites of failure for the stage III patients were the peritoneum (3 patients, 10%), PANs (2 patients, 7%), and lung (2 patients, 7%).
  • The five-year DFS rate was 93%, 100% and 74% for the stage I, II and III patients, respectively.
  • The major patterns of failure for stage III patients were peritoneal seeding and distant metastasis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2001 Feb;80(2):233-8 [11161865.001]
  • [Cites] Gynecol Oncol. 2000 Oct;79(1):79-85 [11006036.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):834-8 [15927414.001]
  • [Cites] Gynecol Oncol. 2005 Jun;97(3):755-63 [15913742.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Aug 1;42(1):101-4 [9747826.001]
  • [Cites] Gynecol Oncol. 1996 Aug;62(2):278-81 [8751561.001]
  • [Cites] Gynecol Oncol. 1995 May;57(2):138-44 [7729725.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1992 Nov;4(6):373-6 [1463690.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;22(5):905-11 [1555983.001]
  • [Cites] Gynecol Oncol. 1989 Apr;33(1):68-70 [2703169.001]
  • [Cites] J Natl Cancer Inst. 1988 Apr 20;80(4):276-8 [3280811.001]
  • [Cites] Radiobiol Radiother (Berl). 1987;28(4):519-28 [3685293.001]
  • [Cites] Obstet Gynecol. 1980 Oct;56(4):419-27 [6999399.001]
  • [Cites] Cancer Treat Rep. 1979 Jan;63(1):21-7 [369691.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):168-73 [15093913.001]
  • [Cites] Gynecol Oncol. 2004 Mar;92(3):744-51 [14984936.001]
  • [Cites] Gynecol Oncol. 2003 May;89(2):236-42 [12713986.001]
  • [Cites] Gynecol Oncol. 2002 Dec;87(3):274-80 [12468325.001]
  • [Cites] Gynecol Oncol. 2002 Mar;84(3):437-42 [11855884.001]
  • (PMID = 19771273.001).
  • [ISSN] 1598-2998
  • [Journal-full-title] Cancer research and treatment : official journal of Korean Cancer Association
  • [ISO-abbreviation] Cancer Res Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2741680
  • [Keywords] NOTNLM ; Endometrial neoplasms / Patterns of failure / Postoperative radiation therapy
  •  go-up   go-down


16. Jakse G, Kapp KS, Geyer E, Oechs A, Maier A, Gabor S, Jüttner FM: IORT and external beam irradiation (EBI) in clinical stage I-II NSCLC patients with severely compromised pulmonary function: an 52-patient single-institutional experience. Strahlenther Onkol; 2007 Dec;183 Spec No 2:24-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IORT and external beam irradiation (EBI) in clinical stage I-II NSCLC patients with severely compromised pulmonary function: an 52-patient single-institutional experience.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Carcinoma, Non-Small-Cell Lung / radiotherapy. Carcinoma, Non-Small-Cell Lung / surgery. Carcinoma, Squamous Cell / radiography. Carcinoma, Squamous Cell / surgery. Lung Neoplasms / radiotherapy. Lung Neoplasms / surgery
  • [MeSH-minor] Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Lung / pathology. Lymph Node Excision. Male. Middle Aged. Neoplasm Staging. Radiotherapy Dosage. Survival Analysis. Thoracotomy

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18167003.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


17. Rena O, Carsana L, Cristina S, Papalia E, Massera F, Errico L, Bozzola C, Casadio C: Lymph node isolated tumor cells and micrometastases in pathological stage I non-small cell lung cancer: prognostic significance. Eur J Cardiothorac Surg; 2007 Dec;32(6):863-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymph node isolated tumor cells and micrometastases in pathological stage I non-small cell lung cancer: prognostic significance.
  • OBJECTIVE: To determine the prevalence and prognostic significance of lymph node micrometastases and isolated tumor cells (ITC) in patients submitted for radical resection for pathological stage I non-small cell lung cancer (NSCLC).
  • Surgical specimens were submitted to pathological routine examinations to define histotype, grade, stage, vascular invasion, necrosis and tumor proliferative index.
  • RESULTS: By histological examination, there were 36 squamous-cell carcinoma, 38 adenocarcinoma and 13 large-cell carcinoma.
  • Significant correlation was observed between micrometastases or ITC and adenocarcinoma (p=0.03) and the absence of necrosis (p=0.05).
  • DISCUSSION: Micrometastases or ITC to regional lymph nodes are demonstrated to be not a rare aspect of pathological stage I resected lung cancer.
  • In our series, the presence of lymph nodes micrometastases does not affect long-term disease-free survival.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / secondary. Lung Neoplasms / pathology


18. Horio H, Hijima T, Sakaguchi K, Kuwabara K: Mediastinal Castleman disease associated with pulmonary carcinoma, mimicking N2 stage lung cancer. Jpn J Thorac Cardiovasc Surg; 2005 May;53(5):286-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mediastinal Castleman disease associated with pulmonary carcinoma, mimicking N2 stage lung cancer.
  • A 67-year-old man presented at our hospital with suspected right lung cancer with mediastinal and hilar lymphadenopathy.
  • Final histopathological diagnosis was a poorly differentiated adenocarcinoma of the lung staged as T1NOMO and a coexistent localized hyaline-vascular type of Castleman disease.
  • This is a rare case of coexistence of lung cancer and Castleman disease, illustrating the difficulties in distinguishing lymph node metastasis from other pulmonary diseases.
  • [MeSH-major] Adenocarcinoma / epidemiology. Giant Lymph Node Hyperplasia / epidemiology. Lung Neoplasms / epidemiology. Mediastinal Diseases / epidemiology

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Pulmonary Disease.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Thorac Cardiovasc Surg. 2003 Dec;126(6):1943-51 [14688710.001]
  • [Cites] Radiology. 1998 Oct;209(1):221-8 [9769835.001]
  • [Cites] Am Rev Respir Dis. 1988 Jul;138(1):184-234 [3059866.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1276-80 [7632932.001]
  • [Cites] Cancer. 1972 Mar;29(3):670-83 [4551306.001]
  • [Cites] Am J Surg Pathol. 1983 Apr;7(3):211-31 [6837832.001]
  • [Cites] Cancer. 1956 Jul-Aug;9(4):822-30 [13356266.001]
  • [Cites] Ann Thorac Surg. 1995 May;59(5):1162-5 [7733713.001]
  • [Cites] Clin Nucl Med. 2003 Apr;28(4):325-6 [12642717.001]
  • [Cites] Am J Surg Pathol. 1984 Apr;8(4):287-93 [6711739.001]
  • (PMID = 15952326.001).
  • [ISSN] 1344-4964
  • [Journal-full-title] The Japanese journal of thoracic and cardiovascular surgery : official publication of the Japanese Association for Thoracic Surgery = Nihon Kyobu Geka Gakkai zasshi
  • [ISO-abbreviation] Jpn. J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


19. Dudek AZ, Kmak KL, Koopmeiners J, Keshtgarpour M: Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer. Lung Cancer; 2006 Jan;51(1):89-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
  • BACKGROUND: Only 15% of patients with non-small cell lung cancer (NSCLC) treated with oral epidermal growth factor tyrosine kinase inhibitor gefitinib, as a second-line therapy have objective responses.
  • Fifty percent will have improvement of lung cancer related symptoms.
  • The Log-rank Test and Cox proportional hazards regression were used to assess the effect of the number of previous therapy lines, histology subtype, performance status, gender, stage of disease at initial diagnosis, and presence of skin rash on time to disease progression and overall survival (OS).
  • There were 37 female and 39 male patients; 47 patients had adenocarcinoma, 22 had squamous and 7 had other NSCLC histologies.
  • Six patients had no prior therapy, 23 had one, 32 had two, 8 had three, and 7 had four prior therapies for lung cancer.
  • Patients with adenocarcinoma histology with bronchoalveolar features had superior median time to progression versus other lung cancer histology (14 months versus 3 months, p=0.076), which translated into survival advantage in this group >24 months (95% CI: 0.76, 24+) versus 6.6 months (p=0.0096).
  • We suggest that adenocarcinoma with bronchoalveolar features and the presence of skin rash may be used as predictors of gefitinib benefit.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / secondary. Bronchoalveolar Lavage Fluid / cytology. Carcinoma, Non-Small-Cell Lung / secondary. Exanthema / chemically induced. Lung Neoplasms / pathology. Quinazolines / therapeutic use


20. Zhong XJ, Li DT, Li XL, Mu DB, Zhang XG, Luo JY: [Comparison of the characteristics in recurrence and metastasis between bronchioloalveolar carcinoma and other lung adenocarcinomas]. Ai Zheng; 2007 Jul;26(7):785-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparison of the characteristics in recurrence and metastasis between bronchioloalveolar carcinoma and other lung adenocarcinomas].
  • Although bronchioloalveolar carcinoma is a subtype of lung adenocarcinoma, its biological features are better than those of other lung adenocarcinomas.
  • This study was to analyze differences in metastatic activity between bronchioloalveolar carcinoma and other lung adenocarcinomas.
  • METHODS: The expression of E-Cadherin, Collagen IV, vascular endothelial growth factor receptor-2 (VEGFR-2), matrix metalloproteinase-9 (MMP-9), and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) in 28 specimens of stage I bronchioloalveolar carcinoma confirmed pathologically and 40 specimens of other stage I lung adenocarcinomas were detected by immunohistochemistry.
  • RESULTS: The 5-year survival rate was significantly higher in ths patients with bronchioloalveolar carcinoma than in the patients with other lung adenocarcinomas (88.7% vs. 57.3%, P < 0.05).
  • The intrathoracic recurrence rate was significantly higher and the extrathoracic metastasis rate was significantly lower in the patients with bronchioloalveolar carcinoma than in the patients with other lung adenocarcinomas (75% vs. 33.3%, 25% vs. 66.7%, P < 0.05).
  • The positive rates of Collagen IV, E-Cadherin and TIMP-1 were significantly higher in bronchioloalveolar carcinoma than in other lung adenocarcinomas (78.6% vs. 42.5%, 78.6% vs. 40.0%, 67.5% vs. 42.9%, all P < 0.01).
  • The positive rate of VEGFR-2 was significantly higher in other lung adenocarcinomas than in bronchioloalveolar carcinoma (85.7% vs. 77.5%, P < 0.05).
  • There was no significant difference in the positive rate of MMP-9 between bronchioloalveolar carcinoma and other lung adenocarcinomas (85.0% vs. 78.6%, P = 0.494).
  • CONCLUSION: As compared with other lung adenocarcinomas, stage I bronchioloalveolar carcinoma is less aggressive in clinical behavior and likely to develop intrathoracic recurrence, with less extrathoracic metastases and better prognosis.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Collagen Type IV / metabolism. Lung Neoplasms / pathology. Neoplasm Recurrence, Local

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17626761.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cadherins; 0 / Collagen Type IV; 0 / Tissue Inhibitor of Metalloproteinase-1; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


21. Raso MG, Wistuba II: Molecular pathogenesis of early-stage non-small cell lung cancer and a proposal for tissue banking to facilitate identification of new biomarkers. J Thorac Oncol; 2007 Jul;2(7 Suppl 3):S128-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular pathogenesis of early-stage non-small cell lung cancer and a proposal for tissue banking to facilitate identification of new biomarkers.
  • Non-small cell lung carcinoma (NSCLC) is one of the leading causes of death from cancer in both Eastern and Western countries.
  • For patients with stage I NSCLC, full lobar or more extensive surgical resection is the treatment of choice.
  • However, even among patients with surgically resected, stage I NSCLC, up to 30% of patients die of the disease within 5 years.
  • At present, apart from clinical stage, there are no established cancer-specific clinical variables or biomarkers that reliably identify individuals at increased risk of death after surgical resection-individuals who could be candidates for adjuvant therapy or alternative management strategies.
  • At a recent international workshop, participants discussed a clinical trial to compare radiation therapy with surgery among patients with stage I NSCLC.
  • This study offers the opportunity to prospectively obtain, bank, and analyze tissue and other clinical specimens, which should facilitate the identification of new biomarkers for early detection, prognosis, and therapy in lung cancer.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17603309.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA070907; United States / NCI NIH HHS / CA / P50CA70907
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


22. Bozas GT, Bamias A, Kastritis E, Rodolakis A, Vlahos G, Papadimitriou CA, Markaki S, Dimopoulos MA: Adjuvant chemotherapy with paclitaxel and carboplatin in non-endometrioid carcinoma of the uterus. Eur J Gynaecol Oncol; 2005;26(6):627-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Fifteen patients with Stage IB-IV UPSC or UCCC were treated with a mean of six courses of paclitaxel 175 mg/m3 plus carboplatin AUC 5 at three-week intervals, three to six weeks after undergoing surgery with curative intent.
  • Recurrence rate per Stage was 17% for Stage IB/C, 57% for Stage IIIA/C and 50% for Stage IV.
  • All relapses were abdominopelvic whereas in one case pelvic recurrence was accompanied by lung metastasis.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Papillary / drug therapy. Endometrial Neoplasms / drug therapy

  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16398224.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


23. Karacetin D, Incekara O: Gemcitabine-cisplatin given on day 1 every 3 weeks in advanced non-small cell lung cancer. J BUON; 2006 Apr-Jun;11(2):181-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine-cisplatin given on day 1 every 3 weeks in advanced non-small cell lung cancer.
  • PURPOSE: To determine the activity and toxicity of a higher dose intensity of the gemcitabine plus cisplatin combination in patients with non-small cell lung cancer (NSCLC).
  • NSCLC histological subtypes were: adenocarcinoma 3, large cell carcinoma 3, and squamous cell carcinoma 29.
  • Twenty patients had stage IIIB and 15 stage IV.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / radiotherapy. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17318968.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


24. Mamat S, Ikeda J, Enomoto T, Ueda Y, Rahadiani N, Tian T, Wang Y, Qiu Y, Kimura T, Aozasa K, Morii E: Prognostic significance of CUB domain containing protein expression in endometrioid adenocarcinoma. Oncol Rep; 2010 May;23(5):1221-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of CUB domain containing protein expression in endometrioid adenocarcinoma.
  • High level of CDCP1 expression proved to be a poor prognosticator for lung adenocarcinoma.
  • Here, expression level of CDCP1 was immunohistochemically examined in 110 cases (median age of 54.7 years) of endometrioid adenocarcinoma, and its clinical implications were evaluated.
  • Tumor stage was stage I in 71 cases (64.5%), II in 5 (4.5%), III in 28 (25.5%), and IV in 6 (5.5%).
  • Significant positive correlation was observed between low CDCP1 expression and stage (p=0.0091), relapse rate (p=0.0017), and poor prognosis (p=0.0009).
  • Multivariate analysis revealed that low CDCP1 and advanced stage were independent poor prognostic factors for both OS and DFS.
  • These suggested that the attitude of CDCP1 in cancers of lung and endometrium was different.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20372833.001).
  • [ISSN] 1791-2431
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / CDCP1 protein, human; 0 / Cell Adhesion Molecules; 0 / Neoplasm Proteins; 0 / RNA, Messenger
  •  go-up   go-down


25. Castonguay M, Rodrigues G, Vincent M, Malthaner RA, Guo LR: Chemoradiation-induced superior vena cava syndrome: a case report. Can Respir J; 2008 Nov-Dec;15(8):444-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A case of a 54-year-old man who developed superior vena cava syndrome secondary to vascular fibrosis, 30 months after radical chemoradiation for stage III non-small cell lung cancer, is presented.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / epidemiology. Adenocarcinoma / radiotherapy. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Avian Proteins. Brain Neoplasms / radiotherapy. Brain Neoplasms / secondary. Cell Adhesion Molecules. Combined Modality Therapy. Comorbidity. Coronary Artery Bypass. Dose Fractionation. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / epidemiology. Lung Neoplasms / radiotherapy. Male. Middle Aged. Muscle Proteins. Myocardial Infarction / epidemiology. Myocardial Infarction / surgery. Radiotherapy / adverse effects. Time Factors

  • Genetic Alliance. consumer health - Superior vena cava syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Catheter Cardiovasc Interv. 2005 Jul;65(3):416-23 [15926179.001]
  • [Cites] Radiother Oncol. 2004 Nov;73(2):119-31 [15542158.001]
  • [Cites] Radiology. 1998 Jan;206(1):187-93 [9423671.001]
  • [Cites] Tex Heart Inst J. 1995;22(1):103-4 [7787461.001]
  • [Cites] Am Rev Respir Dis. 1990 May;141(5 Pt 1):1114-8 [2339833.001]
  • [Cites] J Vasc Surg. 2003 Aug;38(2):215-23 [12891100.001]
  • [Cites] J Chemother. 2002 Aug;14(4):417-9 [12420862.001]
  • [Cites] Radiother Oncol. 2002 May;63(2):129-45 [12063002.001]
  • [Cites] Thorax. 2000 Mar;55(3):245-6 [10679546.001]
  • [Cites] Ann Thorac Surg. 2006 Jul;82(1):310-2 [16798237.001]
  • (PMID = 19107246.001).
  • [ISSN] 1198-2241
  • [Journal-full-title] Canadian respiratory journal
  • [ISO-abbreviation] Can. Respir. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Avian Proteins; 0 / Bves protein, Gallus gallus; 0 / Cell Adhesion Molecules; 0 / Muscle Proteins
  • [Other-IDs] NLM/ PMC2682168
  •  go-up   go-down


26. Cooke DT, Nguyen DV, Yang Y, Chen SL, Yu C, Calhoun RF: Survival comparison of adenosquamous, squamous cell, and adenocarcinoma of the lung after lobectomy. Ann Thorac Surg; 2010 Sep;90(3):943-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival comparison of adenosquamous, squamous cell, and adenocarcinoma of the lung after lobectomy.
  • BACKGROUND: Primary adenosquamous carcinoma (ASC) of the lung is a rare tumor that may carry a poor prognosis.
  • We examined a national database to see if ASC exhibited distinct clinical behavior from squamous cell (SC) and adenocarcinoma (AC) of the lung.
  • METHODS: This is a retrospective study querying the Surveillance, Epidemiology, and End Results database to identify 872 surgical patients diagnosed with ASC, 7888 with SC, and 12,601 with AC of the lung from 1998 to 2002.
  • Analysis characterized clinical variables to determine patterns of presentation and compared survival among the above three histologic groups after lobectomy for stage I and II disease.
  • Survival after lobectomy for stage I and II disease was significantly reduced in ASC and SC compared with AC (p < 0.0001).
  • Other significant negative predictors of survival included tumor grade of III and IV, stage II, age, and black ethnicity.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / surgery. Carcinoma, Adenosquamous / mortality. Carcinoma, Adenosquamous / surgery. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / surgery. Lung Neoplasms / mortality. Lung Neoplasms / surgery. Pneumonectomy

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20732522.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / UL1 RR024146
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  •  go-up   go-down


27. Ramnath N, Demmy TL, Antun A, Natarajan N, Nwogu CE, Loewen GM, Reid ME: Pneumonectomy for bronchogenic carcinoma: analysis of factors predicting survival. Ann Thorac Surg; 2007 May;83(5):1831-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The aim of this study was to identify risk factors associated with survival after pneumonectomy for non-small cell lung cancer.
  • METHODS: This was a retrospective study of 155 patients who underwent a pneumonectomy for non-small cell lung cancer at Roswell Park Cancer Institute between 1986 and 2002.
  • Squamous cell carcinoma (54%) and adenocarcinoma (33%) were the predominant histologic types.
  • An American Society of Anesthesiology score of less than 3, squamous histology, and lower pathologic stage were significant independent predictors of improved survival.
  • CONCLUSIONS: American Society of Anesthesiology score, histology, pathologic stage, smoking status, and location of the tumor were important predictors of survival in this patient sample.
  • Pneumonectomy for non-small cell lung cancer carries an acceptable operative mortality and provides an important survival benefit.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Bronchogenic / surgery. Carcinoma, Squamous Cell / surgery. Lung Neoplasms / surgery. Pneumonectomy / mortality

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17462408.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


28. Kim TJ, Han DH, Jin KN, Won Lee K: Lung cancer detected at cardiac CT: prevalence, clinicoradiologic features, and importance of full-field-of-view images. Radiology; 2010 May;255(2):369-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung cancer detected at cardiac CT: prevalence, clinicoradiologic features, and importance of full-field-of-view images.
  • PURPOSE: To retrospectively evaluate the prevalence and clinicoradiologic features of lung cancer detected at cardiac computed tomography (CT) and compare the detection rates at different field-of-view (FOV) settings.
  • Patients with lung cancer initially detected at cardiac CT were identified by means of a retrospective search of a lung cancer registry patient database between January 2004 and December 2007.
  • Patients known to have lung cancer at the time of cardiac CT were excluded.
  • The prevalence and clinical and radiologic features of lung cancer were evaluated.
  • The rates of lung cancer detection at three FOVs-limited and full FOV at cardiac scanning and full FOV at thoracic scanning-were compared by using McNemar testing.
  • RESULTS: The prevalence of lung cancer detected at CT was 0.31% (36 of 11654 patients, 16 [44%] never smokers) and was higher in patients suspected or known to have coronary artery disease (0.43% [24 of 5615 patients]) than in asymptomatic screening-examined patients (0.20% [12 of 5924 patients]) (P = .0457).
  • Adenocarcinoma was the most common (in 31 [86%] of 36 patients) histologic subtype.
  • Of 34 non-small cell lung cancers, 23 (68%)-including 16 stage IA cancers-were resectable.
  • CONCLUSION: The prevalence of lung cancer at cardiac CT was 0.31%; and 68% of these malignancies were at a resectable stage.
  • Use of a limited FOV at cardiac scanning led to a large majority (89% [32 of 36 cancers]) of the lung cancers detected at full thoracic scanning being missed; thus, inclusion of the entire chest at cardiac CT is advisable.
  • [MeSH-major] Adenocarcinoma / diagnostic imaging. Lung Neoplasms / diagnostic imaging. Tomography, X-Ray Computed / methods

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Radiologe. 2010 Nov;50(11):951-2 [20963397.001]
  • (PMID = 20413751.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Chijiwa T, Abe Y, Inoue Y, Matsumoto H, Kawai K, Matsuyama M, Miyazaki N, Inoue H, Mukai M, Ueyama Y, Nakamura M: Cancerous, but not stromal, thrombospondin-2 contributes prognosis in pulmonary adenocarcinoma. Oncol Rep; 2009 Aug;22(2):279-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancerous, but not stromal, thrombospondin-2 contributes prognosis in pulmonary adenocarcinoma.
  • However, it is unclear whether TSP-2 expression is related to neovascularization and prognosis in non-small cell lung cancer.
  • The expression of TSP-2 mRNA in carcinoma was significantly higher than normal lung tissues (p<0.0001, Kruskal-Wallis test).
  • The TSP-2 expression levels of the stage II/III pulmonary carcinomas were significantly increased as compared to those of stage I (p=0.0136, Kruskal-Wallis test).
  • We examined TSP-2 protein localizations in the pulmonary adenocarcinoma overexpressing TSP-2 mRNA.
  • Pulmonary adenocarcinoma patients with cancerous TSP-2 expression pattern showed good prognosis (p=0.0322; Fisher's probability exact test).
  • Pulmonary adenocarcinoma patients with non-cancerous TSP-2 expression pattern showed poor prognosis (p=0.0220; Fisher's probability exact test).
  • The stromal TSP-2 expression is not enough to suppress growth of pulmonary adenocarcinoma, while the cancerous TSP-2 expression directly inhibits growth of the carcinoma.
  • [MeSH-major] Adenocarcinoma / mortality. Lung Neoplasms / mortality. Thrombospondins / physiology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19578767.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Thrombospondins; 0 / thrombospondin 2
  •  go-up   go-down


30. Xu AH, Yin YW, Chen FH: [The value of serum endostatin level in early diagnosis of lung cancer]. Zhonghua Yi Xue Za Zhi; 2006 Jul 18;86(27):1916-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The value of serum endostatin level in early diagnosis of lung cancer].
  • OBJECTIVE: To investigate value of serum endostatin level in early diagnosis of lung cancer.
  • METHODS: ELISA was used to detect the level of serum endostatin at in 40 lung carcinoma patients, 18 males and 4 females, aged 59.50 +/- 14.58.
  • The serum endostatin levels of the lung cancer patients at different clinical stage and of different pathological types were analyzed.
  • Twenty patients with benign lung disease and 20 normal persons were used as controls. RESULTS:.
  • (1) The serum endostatin level of the lung cancer patients was 10.71 +/- 9.99) ng/ml, significantly higher than those of the patients with benign lung diseases and the normal persons (4.79 +/- 1.23 ng/ml and 4.51 +/- 1.14 ng/ml, respectively, both P < 0.01). (2) The serum endostatin level of the lung cancer patients at the stage I and II were 13.63 +/- 13.13 ng/ml and 12.35 +/- 5.79 ng/ml respectively, booth significantly higher than that of the patients at the stage III (6.29 +/- 1.64, P = 0.023 and P = 0.023). (3) There were no significant differences in the serum endostatin level among the lung cancer patients with different pathological types. (4) The serum endostatin level of the lung cancer patients after chemotherapy was 7.83 +/- 1.48 ng/ml, significantly higher than that before the chemotherapy (5.59 +/- 1.74, P = 0.04).
  • CONCLUSION:. (1) Rising in lung cancer at stages I and II, level of serum may probably be used as the a sign in early diagnosis of lung cancer. (2) After chemotherapy the level of endostatin has a trend of rising.
  • [MeSH-major] Endostatins / blood. Lung Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Aged. Carcinoma, Small Cell / diagnosis. Carcinoma, Small Cell / pathology. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / pathology. Early Diagnosis. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Serologic Tests

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17064531.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Endostatins
  •  go-up   go-down


31. Chong S, Lee KS, Chung MJ, Kim TS, Kim H, Kwon OJ, Choi YH, Rhee CH: Lung cancer screening with low-dose helical CT in Korea: experiences at the Samsung Medical Center. J Korean Med Sci; 2005 Jun;20(3):402-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung cancer screening with low-dose helical CT in Korea: experiences at the Samsung Medical Center.
  • To determine overall detection rates of lung cancer by low-dose CT (LDCT) screening and to compare histopathologic and imaging differences of detected cancers between high- and low-risk groups, this study included 6,406 asymptomatic Korean adults with >or=45 yr of age who underwent LDCT for lung cancer screening.
  • Lung cancer detection rates were 0.36% (23 of 6,406).
  • Twenty-one non-small cell lung cancers appeared as solid (n=14) or ground-glass opacity (GGO) (n=7) nodules.
  • Therefore, LDCT screening help detect early stage of lung cancer in asymptomatic Korean population with detection rate of 0.36% on a population basis and may be useful for discovering early lung cancer in low-risk group as well as in high-risk group.
  • [MeSH-major] Lung Neoplasms / diagnosis. Mass Screening / methods. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adenocarcinoma / diagnosis. Aged. Aged, 80 and over. Carcinoma, Non-Small-Cell Lung / diagnosis. Carcinoma, Squamous Cell / diagnosis. Female. Humans. Korea. Male. Middle Aged. Risk Factors

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am Rev Respir Dis. 1984 Oct;130(4):549-54 [6091505.001]
  • [Cites] Ann N Y Acad Sci. 2001 Dec;952:124-34 [11795431.001]
  • [Cites] Cancer. 1986 Jun 15;57(12):2427-37 [3697941.001]
  • [Cites] Ann Intern Med. 1989 Aug 1;111(3):232-7 [2665590.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):911-20 [11844811.001]
  • [Cites] Am J Respir Crit Care Med. 2002 Feb 15;165(4):508-13 [11850344.001]
  • [Cites] Radiology. 2002 Mar;222(3):773-81 [11867800.001]
  • [Cites] Chest. 2002 May;121(5):1464-7 [12006429.001]
  • [Cites] Radiology. 2003 Mar;226(3):756-61 [12601181.001]
  • [Cites] J Comput Assist Tomogr. 2004 Jan-Feb;28(1):17-23 [14716227.001]
  • [Cites] Jpn J Clin Oncol. 2004 Feb;34(2):82-5 [15067101.001]
  • [Cites] Am J Med. 1969 Apr;46(4):516-25 [5791000.001]
  • [Cites] Chest. 1984 Jul;86(1):44-53 [6734291.001]
  • [Cites] Chest. 1992 Apr;101(4):1013-8 [1313349.001]
  • [Cites] Cancer. 1995 Jun 15;75(12):2844-52 [7773933.001]
  • [Cites] Radiology. 1996 Dec;201(3):798-802 [8939234.001]
  • [Cites] Chest. 1997 Jun;111(6):1718-23 [9187199.001]
  • [Cites] Radiology. 1998 Oct;209(1):243-9 [9769838.001]
  • [Cites] IARC Sci Publ. 1999;(151):1-572 [10619122.001]
  • [Cites] CA Cancer J Clin. 2000 Jan-Feb;50(1):7-33 [10735013.001]
  • [Cites] Br J Radiol. 2000 Feb;73(866):137-45 [10884725.001]
  • [Cites] Br J Cancer. 2001 Jan 5;84(1):25-32 [11139308.001]
  • [Cites] Am Rev Respir Dis. 1984 Oct;130(4):561-5 [6091507.001]
  • (PMID = 15953860.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2782194
  •  go-up   go-down


32. Fukada T, Yasuno K, Koyama T, Tanaka H, Seike K, Kametaka H, Hayashi T, Hashimoto R, Kawano H, Hasegawa A: [A case of advanced rectal carcinoma with multiple lung metastases responding to irinotecan combined with 5-fluorouracil and l-leucovorin (IFL) as neoadjuvant chemotherapy (NAC)]. Gan To Kagaku Ryoho; 2006 Nov;33(11):1665-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced rectal carcinoma with multiple lung metastases responding to irinotecan combined with 5-fluorouracil and l-leucovorin (IFL) as neoadjuvant chemotherapy (NAC)].
  • We examined the digestive tract and diagnosed stage IV advanced rectal carcinoma with multiple lung metastases.
  • Lung metastatic nodules disappeared.
  • We established a diagnosis of down staging for stage IIIa, and performed a lower anterior resection with D 2 lymph node dissection to allow a curability-A resection.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / surgery. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Rectal Neoplasms / drug therapy. Rectal Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17108739.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 7673326042 / irinotecan; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


33. Sakurai H, Asamura H, Goya T, Eguchi K, Nakanishi Y, Sawabata N, Okumura M, Miyaoka E, Fujii Y, Japanese Joint Committee for Lung Cancer Registration: Survival differences by gender for resected non-small cell lung cancer: a retrospective analysis of 12,509 cases in a Japanese Lung Cancer Registry study. J Thorac Oncol; 2010 Oct;5(10):1594-601
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival differences by gender for resected non-small cell lung cancer: a retrospective analysis of 12,509 cases in a Japanese Lung Cancer Registry study.
  • INTRODUCTION: Women with non-small cell lung cancer (NSCLC) are more likely to have better survival than men.
  • METHODS: In 2005, the Japanese Joint Committee for Lung Cancer Registration performed a nationwide retrospective registry study regarding the prognosis and clinicopathologic profiles of patients who underwent resection for primary lung neoplasms in 1999.
  • Women had a higher incidence of adenocarcinoma (p < 0.001) and stage IA disease (p < 0.001) than men.
  • According to histology, the overall survival of women was significantly better than that of men for both adenocarcinoma (5-YSR, 77.7 versus 61.9%, p = 0.0000) and nonadenocarcinoma (5-YSR, 59.3 versus 53.1%, p = 0.035).
  • In adenocarcinoma, women had a significantly better prognosis than men for pathologic stage I/II disease.
  • However, in nonadenocarcinoma, there was no significant prognostic difference between the two genders in pathologic stage I/II disease.
  • CONCLUSIONS: Women with NSCLC, especially with an adenocarcinoma histology, had better survival than men.
  • Women were more likely to have adenocarcinoma and stage IA disease, which might account for the better prognosis in women.
  • [MeSH-major] Adenocarcinoma / mortality. Carcinoma, Adenosquamous / pathology. Carcinoma, Large Cell / mortality. Carcinoma, Non-Small-Cell Lung / mortality. Carcinoma, Squamous Cell / mortality. Lung Neoplasms / mortality


34. Choi N, Son DS, Song I, Lee HS, Lim YS, Song MS, Lim DS, Lee J, Kim H, Kim J: RASSF1A is not appropriate as an early detection marker or a prognostic marker for non-small cell lung cancer. Int J Cancer; 2005 Jul 1;115(4):575-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RASSF1A is not appropriate as an early detection marker or a prognostic marker for non-small cell lung cancer.
  • Aberrant methylation of several tumor suppressor genes often occurs during the pathogenesis of lung cancer.
  • RASSF1A is one of the tumor suppressor genes, and it is frequently inactivated by hypermethylation of its promoter region in a variety of human cancers, including lung cancer.
  • It has recently been suggested that RASSF1A methylation was frequently observed in poorly differentiated tumors, and that it was correlated with adverse survival in lung adenocarcinoma (Tomizawa Y, et al., Clin Cancer Res 2002;8:2362-8).
  • In this study, we investigated the pathogenetic and clinicopathologic significance of RASSF1A methylation for the development and/or progression of non small cell lung cancer (NSCLC).
  • However, there was no association between RASSF1A methylation and the individual clinicopathologic features: TNM stage (p > 0.1), recurrence (p > 0.1), lymphatic permeation (p > 0.1) and smoking duration time (p > 0.1).
  • As a result, the stage proved to be the most important factor (p = 0.0089), more than any other factors such as age, gender, cell type, methylation status, differentiation, smoking duration time, tumor size and lymph node permeation.
  • There was no other significant factor other than stage and age.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / pathology. Tumor Suppressor Proteins / genetics

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 15700308.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / RASSF1 protein, human; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


35. Mino N, Takenaka K, Sonobe M, Miyahara R, Yanagihara K, Otake Y, Wada H, Tanaka F: Expression of tissue inhibitor of metalloproteinase-3 (TIMP-3) and its prognostic significance in resected non-small cell lung cancer. J Surg Oncol; 2007 Mar 1;95(3):250-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of tissue inhibitor of metalloproteinase-3 (TIMP-3) and its prognostic significance in resected non-small cell lung cancer.
  • We conducted a retrospective study of TIMP-3 expression in resected non-small cell lung cancer (NSCLC).
  • Higher TIMP-3 expression was seen in squamous cell carcinoma than in adenocarcinoma (P = 0.001), and reduced TIMP-3 expression was significantly associated with nodal involvement (P = 0.016) and advanced pathologic stage (P = 0.036).
  • CONCLUSIONS: TIMP-3 expression status was significantly correlated with pathologic stage and nodal involvement, and was an independent prognostic factor in resected NSCLC.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / metabolism. Carcinoma, Non-Small-Cell Lung / mortality. Lung Neoplasms / metabolism. Lung Neoplasms / mortality. Tissue Inhibitor of Metalloproteinase-3 / metabolism

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17323339.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tissue Inhibitor of Metalloproteinase-3; 0 / Vascular Endothelial Growth Factor A; EC 3.4.24.24 / Matrix Metalloproteinase 2
  •  go-up   go-down


36. Dertsiz L, Ozbilim G, Kayisli Y, Gokhan GA, Demircan A, Kayisli UA: Differential expression of VASP in normal lung tissue and lung adenocarcinomas. Thorax; 2005 Jul;60(7):576-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of VASP in normal lung tissue and lung adenocarcinomas.
  • We hypothesise that an increase in the expression of VASP is involved in the progression and invasion of lung adenocarcinomas in parallel to tumour progression.
  • A study was undertaken to analyse VASP expression in normal lung tissue and lung adenocarcinomas.
  • METHODS: Human lung tissues with adenocarcinomas (n = 26) were used.
  • Normal lung tissue specimens (n = 14) were taken from areas a standard distance (3 cm) from resected adenocarcinomas of patients who underwent surgical lung resection.
  • RESULTS: Normal lung pneumocytes showed no VASP expression while alveolar macrophages had the strongest immunoreactivity for VASP.
  • Moreover, VASP expression in adenocarcinomas increased significantly with more advanced tumour stage (p < 0.001).
  • CONCLUSIONS: The spatial and differential expression of VASP in normal lung tissue and lung adenocarcinomas suggests that it is likely to be involved in the differentiation of normal lung cells to adenocarcinomas.
  • The significant increase in the expression of VASP in adenocarcinomas in parallel to pathological staging suggests that it may regulate the invasive behaviour of lung adenocarcinomas as adenocarcinoma invasion is increased in more advanced tumours.
  • [MeSH-major] Adenocarcinoma / metabolism. Cell Adhesion Molecules / metabolism. Lung / metabolism. Lung Neoplasms / metabolism. Phosphoproteins / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 2000 Jun 23;101(7):685-8 [10892738.001]
  • [Cites] Ann Thorac Surg. 2005 Mar;79(3):974-9; discussion 979 [15734416.001]
  • [Cites] J Clin Pathol. 2001 Jul;54(7):498-9 [11429418.001]
  • [Cites] Mol Hum Reprod. 2002 Jan;8(1):88-94 [11756574.001]
  • [Cites] Mol Hum Reprod. 2002 Nov;8(11):1023-30 [12397215.001]
  • [Cites] Chest. 2003 Jun;123(6):1858-67 [12796161.001]
  • [Cites] Thorax. 2003 Jul;58(7):639-41 [12832686.001]
  • [Cites] Thorax. 2003 Oct;58(10):892-900 [14514947.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Oct;88(10):5017-26 [14557489.001]
  • [Cites] Cancer Biol Ther. 2004 Jan;3(1):65-70 [14726704.001]
  • [Cites] Thorax. 2004 Jul;59(7):602-7 [15223870.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2004 Aug;24(8):1403-8 [15178555.001]
  • [Cites] Cancer. 1981 Mar 1;47(5):1042-6 [6261919.001]
  • [Cites] Jpn J Cancer Res. 1987 May;78(5):460-6 [3038811.001]
  • [Cites] Am J Clin Pathol. 1988 Sep;90(3):233-9 [2458030.001]
  • [Cites] Eur J Biochem. 1989 Oct 20;185(1):41-50 [2806262.001]
  • [Cites] Jpn J Cancer Res. 1992 Jan;83(1):93-100 [1544877.001]
  • [Cites] Cell Signal. 1992 Mar;4(2):189-99 [1319722.001]
  • [Cites] Cancer. 1993 May 15;71(10):2971-6 [8387872.001]
  • [Cites] J Thorac Cardiovasc Surg. 1993 Jul;106(1):90-4 [8391613.001]
  • [Cites] Eur J Biochem. 1994 Oct 1;225(1):21-7 [7925440.001]
  • [Cites] Eur Respir J. 1994 Jul;7(7):1350-64 [7925916.001]
  • [Cites] Chest. 1997 Jun;111(6):1710-7 [9187198.001]
  • [Cites] EMBO J. 1997 Sep 1;16(17):5433-44 [9312002.001]
  • [Cites] Int J Oncol. 1998 Mar;12(3):553-63 [9472092.001]
  • [Cites] Clin Cancer Res. 1998 Jan;4(1):241-9 [9516978.001]
  • [Cites] Int J Biochem Cell Biol. 1998 Mar;30(3):307-11 [9611773.001]
  • [Cites] Chest. 1999 Apr;115(4):1018-24 [10208203.001]
  • [Cites] Mol Cell Biol. 1999 May;19(5):3696-703 [10207093.001]
  • [Cites] J Thorac Cardiovasc Surg. 1999 Jul;118(1):145-53 [10384197.001]
  • [Cites] Ann Thorac Surg. 2001 Jun;71(6):1759-64 [11426744.001]
  • (PMID = 15994266.001).
  • [ISSN] 0040-6376
  • [Journal-full-title] Thorax
  • [ISO-abbreviation] Thorax
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cell Adhesion Molecules; 0 / Microfilament Proteins; 0 / Phosphoproteins; 0 / vasodilator-stimulated phosphoprotein
  • [Other-IDs] NLM/ PMC1747468
  •  go-up   go-down


37. Yi SZ, Zhang DC, Wang YG, Sun KL: [Clinical features and prognosis of multiple primary tumors of lung combined with other organs--report of 281 cases]. Ai Zheng; 2006 Jun;25(6):731-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical features and prognosis of multiple primary tumors of lung combined with other organs--report of 281 cases].
  • BACKGROUND & OBJECTIVE: Along with the progress of tumor diagnosis, the detection of multiple primary tumors (MPT) of the lung combined with other organs is increasing, but their clinical features and prognosis are unclear yet.
  • This study was to investigate clinical features and prognosis of MPT of the lung combined with other organs.
  • METHODS: Of the 281 patients with MPT of the lung combined with other organs, treated in our hospital from Jan.
  • 1990 to Dec. 2000, 115 had lung cancer diagnosed first (Group A), 116 had other cancers diagnosed first (Group B).
  • The proportion of stage I-II lung cancer was significantly higher in Group A than in Group B (83.9% vs. 63.7%, P<0.01).
  • Second primary cancers occurred in the lung, upper respiratory tract, breast, esophagus, colon, rectum, stomach, and cervix.
  • Smoking was a significant risk factor in the development of MPT of the lung combined with upper respiratory tract.
  • CONCLUSIONS: Lung cancer is closely correlated to upper respiratory tract tumors among MPTs of the lung combined with other organs, and smoking is a potential risk factor.
  • Compared with the patients who had lung cancer diagnosed first, the patients who had other cancers diagnosed first are younger at the first diagnosis, and have longer interval between first and second primary tumors, with better prognosis.
  • [MeSH-major] Lung Neoplasms / diagnosis. Neoplasms, Multiple Primary / diagnosis. Smoking / adverse effects
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Aged. Breast Neoplasms / diagnosis. Breast Neoplasms / pathology. Breast Neoplasms / surgery. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Esophageal Neoplasms / diagnosis. Esophageal Neoplasms / pathology. Esophageal Neoplasms / surgery. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Respiratory Tract Neoplasms / diagnosis. Respiratory Tract Neoplasms / pathology. Respiratory Tract Neoplasms / surgery. Retrospective Studies. Small Cell Lung Carcinoma / diagnosis. Small Cell Lung Carcinoma / pathology. Small Cell Lung Carcinoma / surgery. Survival Rate

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16764770.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


38. Kawasaki T, Yokoi S, Tsuda H, Izumi H, Kozaki K, Aida S, Ozeki Y, Yoshizawa Y, Imoto I, Inazawa J: BCL2L2 is a probable target for novel 14q11.2 amplification detected in a non-small cell lung cancer cell line. Cancer Sci; 2007 Jul;98(7):1070-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BCL2L2 is a probable target for novel 14q11.2 amplification detected in a non-small cell lung cancer cell line.
  • In a previous genome-wide screening of DNA copy number aberrations in a panel of non-small cell lung cancer (NSCLC) cell lines using an in-house bacterial artificial chromosome-based array, we identified a novel amplification at 14q11.2 in HUT29 cells derived from human lung adenocarcinoma.
  • To identify the most likely target for the 14q11.2 amplification, we determined the extent of the amplicon by fluorescence in situ hybridization and then analyzed NSCLC cell lines for the expression levels of 28 genes present within the 1-Mb amplified region.
  • Significant overexpression in the HUT29 cell line with amplification, relatively frequent overexpression in additional NSCLC cell lines compared with an immortalized normal lung epithelial cell line, and reported information about the function of each candidate gene prompted us to characterize the BCL2-like2 (BCL2L2) gene, a prosurvival member of the BCL2 family, as the most likely target for the 14q11.2 amplicon.
  • Immunohistochemical analysis of 61 primary cases of lung adenocarcinoma demonstrated that BCL2L2 overexpression was significantly associated with tumor stage and differentiation status, and tended to be associated with a poorer prognosis.
  • These findings demonstrate that overexpressed BCL2L2, through amplification or other mechanisms, promotes the growth of NSCLC, especially the adenocarcinoma subtype, and might be a therapeutic target.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. Chromosomes, Human, Pair 14. Gene Amplification. Lung Neoplasms / genetics. bcl-X Protein / genetics


39. Li W, Deng J, Jiang P, Tang J: Association of 5'-CpG island hypermethylation of the FHIT gene with lung cancer in southern-central Chinese population. Cancer Biol Ther; 2010 Nov 15;10(10):997-1000
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of 5'-CpG island hypermethylation of the FHIT gene with lung cancer in southern-central Chinese population.
  • The promoter methylation of the FHIT gene has been associated with susceptibility to different cancers, including a role in the early pathogenesis of lung cancer.
  • We investigated the aberrant promoter methylation of FHIT in lung cancer in the Han population of southern-central China.
  • Blood samples from 123 lung cancer patients of different clinical stage and histological grading and 105 healthy control samples were collected.
  • Significant association was found between the lung cancer cases and controls (OR=2.296; 95% CI=1.95-2.705; p < 0.01).
  • Furthermore, we found that aberrant promoter methylation of the FHIT gene showed a highly significant association with clinical stage I and not with clinical stage IV in lung cancer (p < 0.05).
  • These findings suggest FHIT methylation is associated with a higher susceptibility and has a prognostic significance in early stage lung cancer in the Han population of southern-central China and may represent a marker for progressive disease.
  • [MeSH-major] Acid Anhydride Hydrolases / genetics. Adenocarcinoma / genetics. Asian Continental Ancestry Group / genetics. Carcinoma, Squamous Cell / genetics. CpG Islands / genetics. DNA Methylation. Lung Neoplasms / genetics. Neoplasm Proteins / genetics

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20814237.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / fragile histidine triad protein; EC 3.6.- / Acid Anhydride Hydrolases
  •  go-up   go-down


40. Arinç S, Saltürk C, Ertuğrul M, Sulu E, Tuncer L, Nergis S, Selvi U: [Cell type agreement between bronchoscopic biopsy and thoracotomy specimens in primary lung cancer]. Tuberk Toraks; 2007;55(4):378-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cell type agreement between bronchoscopic biopsy and thoracotomy specimens in primary lung cancer].
  • The aim of this study was to evaluate the diagnostic accuracy of bronchial biopsy specimens in establishing the specific cell type in primary lung cancer and to study the influence of several factors on this accuracy.
  • 127 patients with lung cancer diagnosed by bronchoscopic biopsy specimens who subsequently underwent thoracotomy between April 2003 and December 2005 were included.
  • The cell agreement was 92.5% in cases with squamous cell carcinoma and 42.8% in cases with adenocarcinoma (p= 0.002).
  • Stage of the tumor, localization and morphology of the lesion had no effect on cell type agreement (p> 0.05).
  • [MeSH-major] Biopsy, Fine-Needle / standards. Bronchoscopy / standards. Lung Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Female. Humans. Male. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Retrospective Studies. Sensitivity and Specificity. Thoracotomy. Turkey

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18224506.001).
  • [ISSN] 0494-1373
  • [Journal-full-title] Tüberküloz ve toraks
  • [ISO-abbreviation] Tuberk Toraks
  • [Language] tur
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


41. Metintas M, Ak G, Akcayir IA, Metintas S, Erginel S, Alatas F, Yildirim H, Kurt E, Ozkan R: Detecting extrathoracic metastases in patients with non-small cell lung cancer: Is routine scanning necessary? Lung Cancer; 2007 Oct;58(1):59-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detecting extrathoracic metastases in patients with non-small cell lung cancer: Is routine scanning necessary?
  • There is controversy over whether to scan extrathoracic sites for metastases in patients with non-small cell lung cancer (NSCLC).
  • Bone metastases were determined by focal skeleton pains, elevated serum alkaline phosphatase levels, adenocarcinoma, KPS</=70, sensitivity of 90.6, specificity of 12.7, PPV of 16.3, NPV of 87.8, and silent metastases rate (SMR) of 9.4%.
  • Brain metastases were determined by neurological symptoms, adenocarcinoma, hematocrite <40 for men and <35 for women, KPS</=70, sensitivity of 89.9, specificity of 7.9, PPV of 9.2, NPV of 88.3, and SMR of 10.1%.
  • Of the 224 patients with stage I and II disease, 73 had metastasis with a rate of 10.9% silent metastasis.
  • [MeSH-major] Abdominal Neoplasms / secondary. Bone Neoplasms / secondary. Brain Neoplasms / secondary. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / pathology


42. Tanaka J, Tajima S, Ito R, Shimaoka Y, Kuriyama H, Kagamu H, Terada M, Takada T, Gejyo F, Suzuki E, Yoshizawa H, Narita I: [A case of non-small cell lung carcinoma dying of acute respiratory failure due to aerogenous metastasis]. Nihon Kokyuki Gakkai Zasshi; 2009 Jul;47(7):652-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of non-small cell lung carcinoma dying of acute respiratory failure due to aerogenous metastasis].
  • At the time of admission the chest X-ray film showed infiltrative shadows in the left middle and lower lung fields.
  • Our investigation revealed primary mucinous type bronchioloalveolar carcinoma in the left lung (cT4N2M1 Stage IV).
  • However the ground-glass appearance appeared in the right lung a few days later.
  • Necropsy findings revealed bronchioloalveolar carcinoma in the right lung suggesting aerogenous metastasis.
  • Considering these facts together, we diagnosed non-small cell lung carcinoma dying of acute respiratory failure due to aerogenous metastasis.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / secondary. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / pathology. Respiratory Insufficiency / etiology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Respiratory Failure.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19637811.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


43. Casali C, Cucca M, Rossi G, Barbieri F, Iacuzio L, Bagni B, Uliano M: The variation of prognostic significance of Maximum Standardized Uptake Value of [18F]-fluoro-2-deoxy-glucose positron emission tomography in different histological subtypes and pathological stages of surgically resected Non-Small Cell Lung Carcinoma. Lung Cancer; 2010 Aug;69(2):187-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The variation of prognostic significance of Maximum Standardized Uptake Value of [18F]-fluoro-2-deoxy-glucose positron emission tomography in different histological subtypes and pathological stages of surgically resected Non-Small Cell Lung Carcinoma.
  • The SUVmax values resulted significantly related to histological subtypes (p<0.001), histological grading (p<0.001), and pathologic stage (p<0.001).
  • SUVmax still remain a significant predictor of survival in Stage IB (2-year DSS of 100% for SUVmax < or =6.7; 51% for SUVmax >6.7, p=0.016).
  • The optimal cut-off values of SUVmax to predict prognosis were 5 for adenocarcinoma (p=0.027) and 10.7 for other non-adenocarcinoma NSCLC subtypes (p=0.010).
  • These histologic-specific cut-offs resulted significantly related to survival when stratified for stage: 2-year DSS for Stage IB adenocarcinoma were 100% for SUV< or =5 and 40% for SUVmax >5 (p=0.051); 2-year DSS for Stage IB non-adenocarcinoma were 83% for SUVmax < or =10.7 and 26% for SUVmax >10.7 (p=0.018).
  • In conclusion, SUVmax represents a significant prognostic factor in surgically resected NSCLC but a great variability between different histological subtypes, even when adjusted for stage, is present and could be considered when planning future trials on prognostic role of FDG uptake.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / diagnosis. Fluorodeoxyglucose F18 / pharmacokinetics. Lung Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19942313.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


44. Westphal FL, Lima LC, Andrade EO, Lima Netto JC, Silva AS, Carvalho BC: Characteristics of patients with lung cancer in the city of Manaus, Brazil. J Bras Pneumol; 2009 Feb;35(2):157-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics of patients with lung cancer in the city of Manaus, Brazil.
  • OBJECTIVE: To analyze the characteristics of patients with lung cancer.
  • METHODS: A retrospective descriptive study of patients receiving a histopathological diagnosis of lung cancer between 1995 and 2002 in the city of Manaus, Brazil.
  • The following histological types were identified: squamous cell carcinoma, 62.8%; adenocarcinoma, 24.7%; small cell carcinoma, 9.1%; and large cell carcinoma, 3.4%.
  • CONCLUSIONS: In this group of patients with lung cancer, survival rates were considerably lower than those reported in the literature.
  • This might be attributable to the limited access to the specialized health care system and the advanced stage of the disease at diagnosis.
  • [MeSH-major] Carcinoma, Large Cell / mortality. Carcinoma, Squamous Cell / mortality. Lung Neoplasms / mortality. Small Cell Lung Carcinoma / mortality
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / therapy. Brazil / epidemiology. Chi-Square Distribution. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Sex Factors. Survival Rate

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19287919.001).
  • [ISSN] 1806-3756
  • [Journal-full-title] Jornal brasileiro de pneumologia : publicaça̋o oficial da Sociedade Brasileira de Pneumologia e Tisilogia
  • [ISO-abbreviation] J Bras Pneumol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Brazil
  •  go-up   go-down


45. Feldser DM, Kostova KK, Winslow MM, Taylor SE, Cashman C, Whittaker CA, Sanchez-Rivera FJ, Resnick R, Bronson R, Hemann MT, Jacks T: Stage-specific sensitivity to p53 restoration during lung cancer progression. Nature; 2010 Nov 25;468(7323):572-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage-specific sensitivity to p53 restoration during lung cancer progression.
  • Here we show that restoration of p53 in established murine lung tumours leads to significant but incomplete tumour cell loss specifically in malignant adenocarcinomas, but not in adenomas.
  • Our observations also underscore that the p53 pathway is not engaged by low levels of oncogene activity that are sufficient for early stages of lung tumour development.
  • These data suggest that restoration of pathways important in tumour progression, as opposed to initiation, may lead to incomplete tumour regression due to the stage-heterogeneity of tumour cell populations.
  • [MeSH-major] Adenocarcinoma / physiopathology. Adenoma / physiopathology. Disease Progression. Lung Neoplasms / physiopathology. Tumor Suppressor Protein p53 / metabolism


46. Wang XC, Wang SY, Yang S, Ding Y, Shang Y: [Late course three-dimensional conformal radiotherapy in patients with stage III non-small cell lung cancer]. Di Yi Jun Yi Da Xue Xue Bao; 2005 Jun;25(6):726-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Late course three-dimensional conformal radiotherapy in patients with stage III non-small cell lung cancer].
  • OBJECTIVE: To evaluate the therapeutic efficacy and radiation complications of late course three-dimensional conformal radiotherapy (3DCRT) in patients with stage III non-small cell lung cancer (NSCLC).
  • METHODS: Eighty-six patients with stage III NSCLC were randomly divided into group A (n=42) receiving conventional radiotherapy at the total dose of 66 to 70 Gy in 33 to 35 fractions completed in 6 to 7 weeks and group B (n=44) with late course 3DCRT at the dose of 24-30 Gy in 6 fractions (400-500 cGy per fraction every other day) after 40 Gy conventional radiotherapy, completed in 5 to 6 weeks.
  • The 1- and 2-year survival rates of the patients in group A and B were 62.5% vs 78.0%, and 40.0% vs 53.7% respectively, without significant difference (P>0.05).
  • The later stage radiation complications in the two groups were grade I to II radiation lung fibrosis, occurring at a similar rate between the two groups.
  • CONCLUSION: Late course 3DCRT produces better therapeutic effects than conventional radiotherapy in patients with stage III NSCLC.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / radiotherapy. Lung Neoplasms / radiotherapy. Radiotherapy, Conformal / methods
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Adult. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy Dosage

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15958322.001).
  • [ISSN] 1000-2588
  • [Journal-full-title] Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA
  • [ISO-abbreviation] Di Yi Jun Yi Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


47. Ho C, Ross H, Davies A: Phase II trial of premetrexed in patients with selected stage IIIB/IV bronchioloalveolar carcinoma. Clin Lung Cancer; 2006 Nov;8(3):220-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of premetrexed in patients with selected stage IIIB/IV bronchioloalveolar carcinoma.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / drug therapy. Antineoplastic Agents / therapeutic use. Glutamates / therapeutic use. Guanine / analogs & derivatives. Lung Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. GUANINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17239300.001).
  • [ISSN] 1525-7304
  • [Journal-full-title] Clinical lung cancer
  • [ISO-abbreviation] Clin Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine
  •  go-up   go-down


48. Syrigos KN, Vansteenkiste J, Parikh P, von Pawel J, Manegold C, Martins RG, Simms L, Sugarman KP, Visseren-Grul C, Scagliotti GV: Prognostic and predictive factors in a randomized phase III trial comparing cisplatin-pemetrexed versus cisplatin-gemcitabine in advanced non-small-cell lung cancer. Ann Oncol; 2010 Mar;21(3):556-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic and predictive factors in a randomized phase III trial comparing cisplatin-pemetrexed versus cisplatin-gemcitabine in advanced non-small-cell lung cancer.
  • BACKGROUND: Baseline patient and disease characteristics are investigated in non-small-cell lung cancer (NSCLC) in an effort to predict response to treatment and optimize patients' outcomes.
  • METHODS: Cox-adjusted models were used to further analyze a randomized phase III study in 1725 chemonaive patients with stage IIIB or IV NSCLC and Eastern Cooperative Oncology Group performance status (PS) of zero or one who received cisplatin plus pemetrexed (CP; C, 75 mg/m(2) and P, 500 mg/m(2)) or cisplatin plus gemcitabine (CG; C, 75 mg/m(2) and G, 1250 mg/m(2)) every 21 days.
  • Gender, ethnicity, disease stage, smoking status, and PS were not predictive in either treatment arm but were shown to be prognostic in the nonsquamous population, consistent with the results in the overall NSCLC population.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. GUANINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19828561.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 0W860991D6 / Deoxycytidine; 5Z93L87A1R / Guanine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


49. Rostad H, Naalsund A, Strand TE, Jacobsen R, Talleraas O, Norstein J: Results of pulmonary resection for lung cancer in Norway, patients older than 70 years. Eur J Cardiothorac Surg; 2005 Feb;27(2):325-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of pulmonary resection for lung cancer in Norway, patients older than 70 years.
  • OBJECTIVE: Surgical resection for lung cancer is the mainstay of curative treatment, but studies regarding postoperative results and long term outcome in the elderly have differed.
  • The purpose of the present study was to assess the early and long-term results of surgical resection in patients more than 70 years of age.
  • This investigation included all patients more than 70 years of age resected for lung cancer in the time period 1993-2000.
  • For results of long-time follow-up only patients operated on between 1993 and 1998 were included.
  • The majority of patients had tumor categorized as clinical stage (cStage) Ia and Ib.
  • CONCLUSIONS: Lung cancer surgery appears to be a relatively safe procedure even in the elderly.
  • However, when old people survive the postoperative period the long term prognosis seems favorable.
  • [MeSH-major] Lung / surgery. Lung Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / surgery. Aged. Aged, 80 and over. Carcinoma, Non-Small-Cell Lung / mortality. Carcinoma, Non-Small-Cell Lung / surgery. Carcinoma, Small Cell / mortality. Carcinoma, Small Cell / surgery. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / surgery. Female. Humans. Male. Neoplasm Staging. Norway / epidemiology. Pneumonectomy / methods. Postoperative Complications / mortality. Sex Factors. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Cardiothorac Surg. 2005 Jul;28(1):182; author reply 182-3 [15939596.001]
  • (PMID = 15691690.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


50. Machida EO, Brock MV, Hooker CM, Nakayama J, Ishida A, Amano J, Picchi MA, Belinsky SA, Herman JG, Taniguchi S, Baylin SB: Hypermethylation of ASC/TMS1 is a sputum marker for late-stage lung cancer. Cancer Res; 2006 Jun 15;66(12):6210-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypermethylation of ASC/TMS1 is a sputum marker for late-stage lung cancer.
  • We studied this for the proapoptotic gene ASC/TMS1 in lung cancer and used the findings to develop a sputum marker.
  • ASC/TMS1 protein levels are reduced in all lung cancer types (30 of 40; 75%) but not in 10 preinvasive lesions.
  • Hypermethylation of ASC/TMS1 is also associated with invasive cancers (41 of 152 or 27.0% of all lung cancer types) with variation in incidence between histopathologic types including 32.1% (26 of 81) of adenocarcinomas, 13.2% (7 of 53) of squamous cell carcinomas, 38.5% (5 of 13) of large-cell carcinomas, and 60% (3 of 5) of small-cell lung cancers.
  • The hypermethylation is particularly correlated with late tumor stages being present in only 14% of stage I but 60% of later-stage tumors.
  • The incidence of ASC/TMS1 hypermethylation in sputum DNA fully mimics the tissue findings being present in only 2% (2 of 85) of high-risk, cancer-free smokers, 15% (3 of 18) of patients with stage I non-small-cell lung cancer (NSCLC), but 41% of patients with stage III NSCLC (18 of 44), including 56% (10 of 18) of those with adenocarcinoma.
  • Importantly, sputum is positive for this marker in 24% (10 of 42) of very high risk, clinically cancer-free individuals previously resected for stage I NSCLC.
  • Thus, hypermethylation of ASC/TMS1 is a marker for late-stage lung cancer and, in sputum, could predict prognosis in patients resected for early-stage disease.
  • [MeSH-major] Biomarkers, Tumor / genetics. Cytoskeletal Proteins / genetics. DNA Methylation. Lung Neoplasms / genetics. Lung Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Aged. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. DNA, Neoplasm / genetics. DNA, Neoplasm / metabolism. Disease Progression. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Risk Factors. Sputum / metabolism

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Cancer Res. 2007 Jan 1;67(1):427
  • (PMID = 16778195.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA058184; United States / NCI NIH HHS / CA / CA095568; United States / NCI NIH HHS / CA / CA097356; United States / NCI NIH HHS / CA / CA37403; United States / NCI NIH HHS / CA / CA89551
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cytoskeletal Proteins; 0 / DNA, Neoplasm; 0 / PYCARD protein, human
  •  go-up   go-down


51. Gallegos Ruiz MI, Floor K, Roepman P, Rodriguez JA, Meijer GA, Mooi WJ, Jassem E, Niklinski J, Muley T, van Zandwijk N, Smit EF, Beebe K, Neckers L, Ylstra B, Giaccone G: Integration of gene dosage and gene expression in non-small cell lung cancer, identification of HSP90 as potential target. PLoS One; 2008;3(3):e0001722
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Integration of gene dosage and gene expression in non-small cell lung cancer, identification of HSP90 as potential target.
  • BACKGROUND: Lung cancer causes approximately 1.2 million deaths per year worldwide, and non-small cell lung cancer (NSCLC) represents 85% of all lung cancers.
  • Understanding the molecular events in non-small cell lung cancer (NSCLC) is essential to improve early diagnosis and treatment for this disease.
  • METHODOLOGY AND PRINCIPAL FINDINGS: In an attempt to identify novel NSCLC related genes, we performed a genome-wide screening of chromosomal copy number changes affecting gene expression using microarray based comparative genomic hybridization and gene expression arrays on 32 radically resected tumor samples from stage I and II NSCLC patients.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. Gene Dosage. Gene Expression Regulation, Neoplastic. HSP90 Heat-Shock Proteins / genetics. Lung Neoplasms / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / secondary. Carcinoma, Large Cell / genetics. Carcinoma, Large Cell / metabolism. Carcinoma, Large Cell / secondary. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / secondary. Chromosome Aberrations. Chromosomes, Human, Pair 14 / genetics. Female. Follow-Up Studies. Genome, Human. Humans. Male. Neoplasm Staging. Oligonucleotide Array Sequence Analysis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate. Tumor Cells, Cultured


52. Meguid RA, Hooker CM, Harris J, Xu L, Westra WH, Sherwood JT, Sussman M, Cattaneo SM 2nd, Shin J, Cox S, Christensen J, Prints Y, Yuan N, Zhang J, Yang SC, Brock MV: Long-term survival outcomes by smoking status in surgical and nonsurgical patients with non-small cell lung cancer: comparing never smokers and current smokers. Chest; 2010 Sep;138(3):500-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival outcomes by smoking status in surgical and nonsurgical patients with non-small cell lung cancer: comparing never smokers and current smokers.
  • BACKGROUND: Survival outcomes of never smokers with non-small cell lung cancer (NSCLC) who undergo surgery are poorly characterized.
  • RESULTS: Never smokers were significantly more likely than current smokers to be women (P < .01), older (P < .01), and to have adenocarcinoma (P < .01) and bronchioloalveolar carcinoma (P < .01).
  • No statistically significant differences existed in stage distribution at presentation for the analytic cohort (P = .35) or for the subgroup undergoing surgery (P = .24).
  • The strongest risk factors of mortality among patients with NSCLC who underwent surgery were advanced stage (adjusted hazard ratio, 3.43; 95% CI, 2.32-5.07; P < .01) and elevated American Society of Anesthesiologists classification (adjusted hazard ratio, 2.18; 95% CI, 1.40-3.40; P < .01).
  • CONCLUSIONS: Our findings suggest that smoking status at time of lung cancer diagnosis has little impact on the long-term survival of patients with NSCLC, especially after curative surgery.
  • Despite different etiologies between lung cancer in never and current smokers the prognosis is equally dismal.


53. Tomoda Y, Kai T, Inata J, Miyazaki K, Murai H, Yamaoka N, Kuraoka T: [Central diabetes insipidus caused by pituitary metastasis of lung cancer]. Nihon Kokyuki Gakkai Zasshi; 2005 Dec;43(12):751-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Central diabetes insipidus caused by pituitary metastasis of lung cancer].
  • After examination, lung cancer (adenocarcinoma T1NOM1, Stage IV) and central diabitus insipidus caused by pituitary metastasis of lung cancer, were diagnosed.
  • However, his lung cancer progressed.
  • Diabitus insipidus caused by lung cancer is rare.
  • [MeSH-major] Adenocarcinoma / secondary. Diabetes Insipidus, Neurogenic / etiology. Lung Neoplasms / pathology. Pituitary Neoplasms / secondary


54. Fan Y, Jiang Y, Chang R, Yao S, Hu P, Qiao Y: [Retrospective analysis of screening results of lung cancer cases among occupational population at high risk of lung cancer]. Zhongguo Fei Ai Za Zhi; 2007 Apr 20;10(2):102-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Retrospective analysis of screening results of lung cancer cases among occupational population at high risk of lung cancer].
  • BACKGROUND: Lung cancer has become the leading cause of the cancer death in China.
  • Population-based lung cancer screening is still in controversy.
  • The objective of this study is to analyze the effect of annual chest radiography and sputum cytological screening conducted in high lung cancer risk population who were exposed to work related carcinogens.
  • METHODS: A retrospective analysis was conducted to evaluate the screening results of the lung cancer cases diagnosed from 1992 to 2001 in the miners of Yunnan tin mine.
  • By December 31, 2001, 433 lung cancer cases had been confirmed, 371 cases out of them had cytological/pathological evidence, and 55.0% were squamous cell carcinoma followed by adenocarcinoma and small cell carcinoma.
  • Stage I or II accounted for 24%.
  • 80.8% of early stage cases had at least one previous positive finding from screening.
  • CONCLUSIONS: Annual lung cancer screening with combination of chest radiography and sputum cytology play some extent role in early detection of lung cancer in high risk population.
  • The results may provide some primary data for lung cancer screening in special population who are at high risk of lung cancer in China.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21114930.001).
  • [ISSN] 1009-3419
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


55. Yang L, Lu QY, Wu MN, An TT, Zhao J, Guo QZ, Duan JC, Wang J: [A retrospective analysis: comparison of the clinical characteristics and prognosis in elderly and young patients with locally advanced or metastatic non-small cell lung cancer.]. Zhonghua Jie He He Hu Xi Za Zhi; 2009 Nov;32(11):830-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A retrospective analysis: comparison of the clinical characteristics and prognosis in elderly and young patients with locally advanced or metastatic non-small cell lung cancer.].
  • OBJECTIVE: To investigate whether the clinical characteristics, treatment modalities and prognosis of elderly (>/= 70 years) patients with advanced non-small cell lung cancer (NSCLC) differed from those of young (</= 45 years) patients.
  • (1) Women, adenocarcinoma and stage IV disease were more common in young patients (46.2% vs 22.3%, P = 0.000, 71.3% vs 54.7%, P = 0.001 and 72.7% vs 61.7%, P = 0.026), when compared with elderly patients.
  • CONCLUSION: Women, adenocarcinoma and stage IV disease were more common in young patients when compared with elderly patients.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung. Lung Neoplasms


56. Ren YJ, Zhang QY: [Expression of survivin and its clinical significance in non-small cell lung cancer]. Beijing Da Xue Xue Bao; 2005 Oct 18;37(5):504-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of survivin and its clinical significance in non-small cell lung cancer].
  • OBJECTIVE: To investigate the expression of survivin in non-small cell lung cancer (NSCLC) and analyze its relationship with clinico pathological features and the expression of p53.
  • The cytoplasmic and nuclear immunoreactivities in squamous cell carcinoma (57.6%, 19/33) were higher than that in adenocarcinoma (25%, 7/28) and there was significant difference (P<0.05).
  • Survivin expression levels did not correlate with the patient's gender, age, clinical stage, histological differentiation, lymph node metastasis status or survival.
  • It correlated with pathological type that mainly showed the positive expression rate in squamous cell carcinoma was higher than that in adenocarcinoma.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / metabolism. Lung Neoplasms / metabolism. Microtubule-Associated Proteins / biosynthesis. Neoplasm Proteins / biosynthesis
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adult. Aged. Biomarkers / analysis. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Female. Humans. Immunohistochemistry. Inhibitor of Apoptosis Proteins. Male. Middle Aged. Tumor Suppressor Protein p53 / biosynthesis

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16224523.001).
  • [ISSN] 1671-167X
  • [Journal-full-title] Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
  • [ISO-abbreviation] Beijing Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Biomarkers; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


57. Sheng SL, Huang G, Yu B, Qin WX: Clinical significance and prognostic value of serum Dickkopf-1 concentrations in patients with lung cancer. Clin Chem; 2009 Sep;55(9):1656-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance and prognostic value of serum Dickkopf-1 concentrations in patients with lung cancer.
  • Clinical significance of serum DKK1 in lung cancer remains to be determined.
  • By use of this method, we investigated the serum concentrations of DKK1 in 592 patients with malignancies, 72 patients with benign lung disease, and 120 healthy controls.
  • RESULTS: Serum DKK1 concentrations were significantly higher in patients with lung cancer than in patients with other malignant tumors or benign lung diseases and healthy controls.
  • Serum concentrations of DKK1 were decreased significantly in groups of patients with gastric cancer, colorectal cancer, ovarian cancer, and cervical adenocarcinoma compared with healthy controls.
  • Application of both DKK1 and cytokeratin 19 fragment increased sensitivity, correctly identifying 89.6% of the non-small cell lung cancer patients as positive.
  • The use of both DKK1 and neuron-specific enolase increased sensitivity to detect small cell lung cancer to 86.2%.
  • DKK1 concentrations increased with stage, tumor class, and presence of lymph node and distant metastases, regardless of histology and patient age and sex.
  • CONCLUSIONS: DKK1 was preferentially expressed in lung cancer.
  • Increasing concentrations of DKK1were significantly associated with tumor progression and decreased survival in patients with lung cancer. .
  • [MeSH-major] Biomarkers, Tumor / blood. Fluoroimmunoassay / methods. Intercellular Signaling Peptides and Proteins / blood. Lung Neoplasms / blood

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19628661.001).
  • [ISSN] 1530-8561
  • [Journal-full-title] Clinical chemistry
  • [ISO-abbreviation] Clin. Chem.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DKK1 protein, human; 0 / Intercellular Signaling Peptides and Proteins
  •  go-up   go-down


58. Dooms C, Verbeken E, Stroobants S, Vansteenkiste J: Biological correlates of the maximum 18-fluoro-2-deoxy-glucose uptake on positron emission tomography in non-small cell lung carcinoma after induction chemotherapy. J Thorac Oncol; 2009 Oct;4(10):1221-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biological correlates of the maximum 18-fluoro-2-deoxy-glucose uptake on positron emission tomography in non-small cell lung carcinoma after induction chemotherapy.
  • We aimed to investigate the mechanisms that drive persistent FDG uptake in non-small cell lung carcinoma treated with IC.
  • Although surrogate markers for tumor hypoxia and acidity showed a trend for correlation with increased glycolysis in pretreated stage IIIA-N2 non-small cell lung carcinoma, these markers did not contribute to the recognition of metabolic responders versus nonresponders.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Non-Small-Cell Lung / radionuclide imaging. Fluorodeoxyglucose F18. Lung Neoplasms / radionuclide imaging. Positron-Emission Tomography. Radiopharmaceuticals
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / radionuclide imaging. Adenocarcinoma / therapy. Carcinoma, Large Cell / pathology. Carcinoma, Large Cell / radionuclide imaging. Carcinoma, Large Cell / therapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radionuclide imaging. Carcinoma, Squamous Cell / therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Remission Induction

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19641474.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


59. Mun M, Kohno T: Single-stage surgical treatment of synchronous bilateral multiple lung cancers. Ann Thorac Surg; 2007 Mar;83(3):1146-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single-stage surgical treatment of synchronous bilateral multiple lung cancers.
  • BACKGROUND: The rate of detection of synchronous bilateral multiple lung cancers (SBMLC) has increased.
  • We evaluated applicability and efficacy of single-stage surgical treatment of SBMLC patients encountered in our department.
  • METHODS: In a retrospective examination of 674 patients who underwent surgical treatment of primary lung cancers at our department between 1999 and 2004, single-stage surgical treatment was used in 19 patients.
  • CONCLUSIONS: Single-stage bilateral surgical treatment of SBMLC yielded satisfactory results in our selected patients; however, appearance of new lesions remains a problem.
  • [MeSH-major] Adenocarcinoma / surgery. Adenocarcinoma, Bronchiolo-Alveolar / surgery. Carcinoma, Squamous Cell / surgery. Lung Neoplasms / surgery. Neoplasms, Second Primary / surgery. Pneumonectomy / methods
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Lung Diseases / etiology. Male. Middle Aged. Neoplasm Recurrence, Local. Pneumonia / etiology. Respiratory Tract Fistula / etiology. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17307478.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


60. Campeau MP, Herschtal A, Wheeler G, Mac Manus M, Wirth A, Michael M, Hogg A, Drummond E, Ball D: Local control and survival following concomitant chemoradiotherapy in inoperable stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys; 2009 Aug 1;74(5):1371-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local control and survival following concomitant chemoradiotherapy in inoperable stage I non-small-cell lung cancer.
  • PURPOSE: Concomitant chemoradiotherapy (CRT) increases survival rates compared with radical radiotherapy alone (RT) in Stage III non-small-cell lung cancer (NSCLC), as a result of improved local control.
  • The effect of CRT on local control in Stage I NSCLC is less well documented.
  • We retrospectively reviewed local control and survival following CRT or RT for inoperable Stage I NSCLC patients.
  • METHODS AND MATERIALS: Eligible patients had histologically/cytologically proved inoperable Stage I NSCLC and had undergone complete staging investigations including an F-18 fluorodeoxyglucose positron emission tomography (FDG-PET) scan.
  • CONCLUSIONS: Despite the use of CRT and routine staging with FDG-PET, both local and distant recurrences remain important causes of treatment failure in patients with inoperable stage I NSCLC.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung. Lung Neoplasms
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Combined Modality Therapy / methods. Disease Progression. Dose Fractionation. Female. Humans. Male. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Radiotherapy, Conformal. Regression Analysis. Retrospective Studies. Survival Rate. Taxoids / administration & dosage


61. Girard N, Deshpande C, Azzoli CG, Rusch VW, Travis WD, Ladanyi M, Pao W: Use of epidermal growth factor receptor/Kirsten rat sarcoma 2 viral oncogene homolog mutation testing to define clonal relationships among multiple lung adenocarcinomas: comparison with clinical guidelines. Chest; 2010 Jan;137(1):46-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of epidermal growth factor receptor/Kirsten rat sarcoma 2 viral oncogene homolog mutation testing to define clonal relationships among multiple lung adenocarcinomas: comparison with clinical guidelines.
  • BACKGROUND: The incidence of multiple lung adenocarcinomas is rising, making it difficult to determine the stage and assign treatment in an increasing number of patients following surgery.
  • Clinical guidelines have been developed to distinguish independent non-small cell lung cancers from metastases, that is, criteria developed by Martini and Melamed and the American College of Chest Physicians (ACCP).
  • Here, we report on seven patients in whom epidermal growth factor receptor (EGFR) and Kirsten-rat sarcoma 2 viral oncogene homolog (KRAS) tumor mutation status was used to determine clonal relationships among multiple lung lesions.
  • METHODS: We identified seven patients whose paired lung adenocarcinomas were found to harbor distinct EGFR or KRAS mutations.
  • RESULTS: According to the Martini-Melamed criteria, six of the seven patients had multiple primary lung tumors.
  • EGFR/KRAS mutation testing of multiple lung adenocarcinomas can assist in differentiating multiple primary lung adenocarcinomas from metastatic lesions.
  • [MeSH-major] Adenocarcinoma / genetics. DNA, Neoplasm / genetics. Lung Neoplasms / genetics. Mutation. Neoplasms, Multiple Primary / diagnosis. Proto-Oncogene Proteins / genetics. Receptor, Epidermal Growth Factor / genetics. ras Proteins / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Chest. 2013 Aug;144(2):715-6 [23918129.001]
  • [CommentIn] Chest. 2010 Jan;137(1):3-4 [20051396.001]
  • [CommentIn] Chest. 2013 Aug;144(2):714-5 [23918128.001]
  • (PMID = 19376842.001).
  • [ISSN] 1931-3543
  • [Journal-full-title] Chest
  • [ISO-abbreviation] Chest
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


62. Shah H, Anker CJ, Bogart J, Graziano S, Shah CM: Brain: the common site of relapse in patients with pancoast or superior sulcus tumors. J Thorac Oncol; 2006 Nov;1(9):1020-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS AND MATERIALS: We reviewed 685 charts of patients treated for upper lobe lung cancer between 1997 and 2003.
  • The histology includes 11 patients with adenocarcinoma, seven with non-small cell lung cancer (NSCLC), six with squamous cell carcinoma, four with large cell carcinoma, and one with anaplastic carcinoma.
  • Regarding stage at presentation: seven patients had stage IIB, two had stage IIIA, 16 had stage IIIB, and four had stage IV.
  • Two patients (stage IV) had brain metastasis at the time of presentation and five patients (stage IIB-III) developed brain metastasis at a median time of 10 months after the diagnosis.
  • Stage associated with brain metastasis after diagnosis is two patients for stage IIB, two for stage IIIA, and one for stage IIIB.
  • For the 25 patients with stage IIB to stage III disease, nine (36%) developed distant metastasis after definitive therapy.
  • Histology for seven patients with brain metastasis was four of seven with adenocarcinoma, two of seven with squamous cell carcinoma, and one of seven with NSCLC.
  • [MeSH-major] Brain Neoplasms / epidemiology. Brain Neoplasms / secondary. Lung Neoplasms / pathology. Pancoast Syndrome / epidemiology. Pancoast Syndrome / secondary
  • [MeSH-minor] Adult. Age Distribution. Aged. Aged, 80 and over. Biopsy, Needle. Cohort Studies. Combined Modality Therapy. Female. Humans. Immunohistochemistry. Incidence. Lung / anatomy & histology. Lung / pathology. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Risk Assessment. Sex Distribution. Survival Analysis. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17409988.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Bonanno L, Schiavon M, Nardo G, Bertorelle R, Bonaldi L, Galligioni A, Indraccolo S, Pasello G, Rea F, Favaretto A: Prognostic and predictive implications of EGFR mutations, EGFR copy number and KRAS mutations in advanced stage lung adenocarcinoma. Anticancer Res; 2010 Dec;30(12):5121-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic and predictive implications of EGFR mutations, EGFR copy number and KRAS mutations in advanced stage lung adenocarcinoma.
  • BACKGROUND/AIM: Gefitinib and erlotinib were shown to be particularly effective in a clinically selected subpopulation of non-small cell lung cancer patients (NSCLC): adenocarcinoma histology, non-smoking status, Asian origin and female gender have been associated with improved clinical benefit compared to the unselected NSCLC population.
  • The aim of the present study was to investigate the prognostic and predictive role of EGFR and KRAS analysis in advanced lung adenocarcinomas, selected according to clinical features associated to better response to EGFR tyrosine kinase inhibitors (TKIs), namely female gender and non-smoker or former light smoker status.
  • CONCLUSION: In a group of clinically selected patients, EGFR and KRAS analysis was able to define distinct molecular subsets of lung adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Genes, erbB-1. Genes, ras. Lung Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21187500.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


64. Segawa N, Abe H, Nishida T, Katsuoka Y: [A case of prostatic cancer discovered from lung metastatic lesions]. Hinyokika Kiyo; 2006 Feb;52(2):147-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of prostatic cancer discovered from lung metastatic lesions].
  • Transrectal sextant needle biopsy of the prostate was performed, revealing moderately differentiated adenocarcinoma.
  • Under a diagnosis of stage D2 prostate cancer, we initiated endocrine therapy (luteinizing hormone-releasing hormone analogue depot every 4 weeks and bicalutamide).
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Antineoplastic Agents, Hormonal / administration & dosage. Lung Neoplasms / secondary. Prostate-Specific Antigen / blood. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / pathology


65. Ullrich RT, Zander T, Neumaier B, Koker M, Shimamura T, Waerzeggers Y, Borgman CL, Tawadros S, Li H, Sos ML, Backes H, Shapiro GI, Wolf J, Jacobs AH, Thomas RK, Winkeler A: Early detection of erlotinib treatment response in NSCLC by 3'-deoxy-3'-[F]-fluoro-L-thymidine ([F]FLT) positron emission tomography (PET). PLoS One; 2008;3(12):e3908
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Inhibition of the epidermal growth factor receptor (EGFR) has shown clinical success in patients with advanced non-small cell lung cancer (NSCLC).
  • Somatic mutations of EGFR were found in lung adenocarcinoma that lead to exquisite dependency on EGFR signaling; thus patients with EGFR-mutant tumors are at high chance of response to EGFR inhibitors.
  • METHODOLOGY/PRINCIPAL FINDINGS: We performed a systematic comparison of 3'-Deoxy-3'-[(18)F]-fluoro-L-thymidine ([(18)F]FLT) and 2-[(18)F]-fluoro-2-deoxy-D-glucose ([(18)F]FDG) positron emission tomography (PET) for their potential to identify response to EGFR inhibitors in a model of EGFR-dependent lung cancer early after treatment initiation.
  • CONCLUSIONS: [(18)F]FLT PET enables robust identification of erlotinib response in EGFR-dependent tumors at a very early stage.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / radionuclide imaging. Dideoxynucleosides. Lung Neoplasms / drug therapy. Lung Neoplasms / radionuclide imaging. Positron-Emission Tomography. Quinazolines / therapeutic use

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] Nuklearmedizin. 2003 Aug;42(4):135-44 [12937692.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11 [15329413.001]
  • [Cites] J Nucl Med. 1986 Feb;27(2):235-8 [3712040.001]
  • [Cites] Cancer Res. 1997 Nov 1;57(21):4838-48 [9354447.001]
  • [Cites] Nat Med. 1998 Nov;4(11):1334-6 [9809561.001]
  • [Cites] J Nucl Med. 2006 Jun;47(6):999-1006 [16741310.001]
  • [Cites] Nat Med. 2006 Jul;12(7):852-5 [16799556.001]
  • [Cites] Clin Cancer Res. 2006 Oct 1;12(19):5659-67 [17020967.001]
  • [Cites] J Nucl Med. 2007 Feb;48(2):277-87 [17268026.001]
  • [Cites] Nat Genet. 2007 Mar;39(3):347-51 [17293865.001]
  • [Cites] Cancer Res. 2007 Dec 1;67(23):11463-9 [18056475.001]
  • [Cites] Clin Cancer Res. 2008 Apr 1;14(7):2049-55 [18381944.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] N Engl J Med. 2000 Jul 27;343(4):254-61 [10911007.001]
  • [Cites] Nucl Med Biol. 2002 Apr;29(3):281-7 [11929696.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12):3331-4 [12067968.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2651-7 [12860940.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • (PMID = 19079597.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dideoxynucleosides; 0 / Ki-67 Antigen; 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; PG53R0DWDQ / alovudine
  • [Other-IDs] NLM/ PMC2592703
  •  go-up   go-down


66. Rusu P, Ciuleanu TE, Cernea D, Pelau D, Gaal V, Cebotaru C, Guttman T, Todor N, Ghilezan N: Concurrent chemoradiotherapy with vinorelbine and a platinum compound followed by consolidation chemotherapy for unresectable stage III non-small cell lung cancer: preliminary results of a phase II study. J BUON; 2007 Jan-Mar;12(1):33-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent chemoradiotherapy with vinorelbine and a platinum compound followed by consolidation chemotherapy for unresectable stage III non-small cell lung cancer: preliminary results of a phase II study.
  • PURPOSE: To determine the efficacy, toxicity and survival of concurrent therapy with vinorelbine and a platinum compound with radiotherapy (RT), followed by consolidation chemotherapy with the same drugs, for locally advanced non small cell lung cancer (NSCLC).
  • PATIENTS AND METHODS: Fifty-seven patients with stage III NSCLC were included in this phase II study: median age 56 years (range 44-71), males / females 49/8, ECOG performance status (PS) 1/2=27/30, stage IIIA/ IIIB 11/46, squamous cell carcinoma 44, adenocarcinoma 7, adenoid cystic carcinoma 1 and large cell carcinoma 5.
  • The 1- and 2- year disease-specific survival was 58% and 29%, and the median overall survival 15 months.
  • CONCLUSION: Preliminary analysis indicates that concurrent vinorelbine and a platinum compound with RT followed by consolidation chemotherapy with the same drugs for advanced stage III NSCLC is well tolerated, has considerable activity and positive impact on survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / radiotherapy. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. AMIFOSTINE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17436399.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Radiation-Protective Agents; 5V9KLZ54CY / Vinblastine; BG3F62OND5 / Carboplatin; M487QF2F4V / Amifostine; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


67. Xi L, Coello MC, Litle VR, Raja S, Gooding WE, Yousem SA, El-Hefnawy T, Landreneau RJ, Luketich JD, Godfrey TE: A combination of molecular markers accurately detects lymph node metastasis in non-small cell lung cancer patients. Clin Cancer Res; 2006 Apr 15;12(8):2484-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A combination of molecular markers accurately detects lymph node metastasis in non-small cell lung cancer patients.
  • Occult lymph node metastasis (micrometastasis) is a good prognostic indicator in non-small cell lung cancer (NSCLC) and could be used to direct adjuvant chemotherapy in stage I patients.
  • PVA and SFTPB are particularly powerful in tumors of squamous and adenocarcinoma histologies, respectively, whereas TACSTD1 is a good general marker for NSCLC metastasis.
  • Long-term follow-up will determine the clinical relevance of these findings.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Hum Genet. 2000 Jan;66(1):6-15 [10631132.001]
  • [Cites] Ann Surg. 2006 Mar;243(3):389-98 [16495705.001]
  • [Cites] J Mol Diagn. 2000 May;2(2):84-91 [11272893.001]
  • [Cites] Ann Oncol. 2001 Jan;12(1):39-46 [11249047.001]
  • [Cites] Int J Cancer. 2001 Feb 15;91(4):433-7 [11251963.001]
  • [Cites] Int J Cancer. 2001 Jul 15;93(2):162-71 [11410861.001]
  • [Cites] J Pathol. 2001 Jul;194(3):298-302 [11439361.001]
  • [Cites] J Thorac Cardiovasc Surg. 2002 Mar;123(3):484-91; discussion 491 [11882819.001]
  • [Cites] J Clin Oncol. 2002 Jul 1;20(13):2930-6 [12089221.001]
  • [Cites] Clin Chem. 2003 Feb;49(2):312-5 [12560358.001]
  • [Cites] Int J Cancer. 2003 Sep 10;106(4):611-8 [12845661.001]
  • [Cites] Am J Surg. 2003 Oct;186(4):324-9 [14553843.001]
  • [Cites] Clin Lung Cancer. 2004 Jan;5(4):214-25 [14967073.001]
  • [Cites] J Clin Oncol. 2004 Jul 1;22(13):2671-80 [15226334.001]
  • [Cites] Cancer Res. 1995 Aug 1;55(15):3417-20 [7542169.001]
  • [Cites] Cancer Res. 1995 Oct 1;55(19):4283-6 [7671236.001]
  • [Cites] N Engl J Med. 1997 Oct 23;337(17):1188-94 [9337377.001]
  • [Cites] J Thorac Cardiovasc Surg. 1997 Oct;114(4):535-43 [9338638.001]
  • [Cites] N Engl J Med. 1998 Jul 23;339(4):223-8 [9673300.001]
  • [Cites] JAMA. 1998 Oct 28;280(16):1410-5 [9801000.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):19-24 [10458213.001]
  • [Cites] Lancet. 1999 Sep 11;354(9182):896-900 [10489948.001]
  • [Cites] Chest. 2005 Feb;127(2):430-7 [15705978.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1099-109 [15709177.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2147-56 [15781625.001]
  • [Cites] N Engl J Med. 2005 Jun 23;352(25):2589-97 [15972865.001]
  • [Cites] Clin Cancer Res. 2005 Jul 1;11(13 Pt 2):5017s-5021s [16000606.001]
  • [Cites] Clin Cancer Res. 2005 Jul 1;11(13 Pt 2):5022s-5026s [16000607.001]
  • [Cites] Br J Cancer. 2000 Jan;82(2):429-35 [10646900.001]
  • (PMID = 16638856.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA094059-04; United States / NCI NIH HHS / CA / R01 CA094059-05; United States / NCI NIH HHS / CA / R01 CA094059; United States / NCI NIH HHS / CA / CA094059-03; United States / NCI NIH HHS / CA / R01 CA094059-01; United States / NCI NIH HHS / CA / R01 CA090665; United States / NCI NIH HHS / CA / R01 CA094059-03; United States / NCI NIH HHS / CA / R01CA90665; United States / NCI NIH HHS / CA / CA094059-02; United States / NCI NIH HHS / CA / CA094059-05; United States / NCI NIH HHS / CA / R01 CA094059-02; United States / NCI NIH HHS / CA / R01 CA094059-04; United States / NCI NIH HHS / CA / CA094059-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / DSG3 protein, human; 0 / Desmoglein 3; 0 / EPCAM protein, human; 0 / Pulmonary Surfactant-Associated Protein B
  • [Other-IDs] NLM/ NIHMS24707; NLM/ PMC1933488
  •  go-up   go-down


68. Rossi D, Dennetta D, Ugolini M, Alessandroni P, Catalano V, Fedeli SL, Giordani P, Casadei V, Baldelli AM, Graziano F, Catalano G: Weekly paclitaxel in elderly patients (aged &gt; or = 70 years) with advanced non-small-cell lung cancer: an alternative choice? Results of a phase II study. Clin Lung Cancer; 2008 Sep;9(5):280-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Weekly paclitaxel in elderly patients (aged > or = 70 years) with advanced non-small-cell lung cancer: an alternative choice? Results of a phase II study.
  • PURPOSE: Paclitaxel and platinum-based chemotherapy is considered to be a standard approach for locally advanced and metastatic non-small-cell lung cancer (NSCLC).
  • The aim of our study was to investigate the activity and safety of weekly paclitaxel in elderly patients with locally advanced (stage IIIB) and metastatic (stage IV) NSCLC.
  • PATIENTS AND METHODS: Twenty-seven patients entered the study; 10 had stage IIIB disease (5 "wet" and 5 "dry"), and 17 had stage IV disease.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Paclitaxel / therapeutic use
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Aged. Aged, 80 and over. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Brain Neoplasms / drug therapy. Brain Neoplasms / secondary. Carcinoma / drug therapy. Carcinoma / secondary. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / secondary. Female. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Male. Prognosis. Salvage Therapy. Survival Rate

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18824450.001).
  • [ISSN] 1525-7304
  • [Journal-full-title] Clinical lung cancer
  • [ISO-abbreviation] Clin Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


69. Hsu LH, Chu NM, Liu CC, Tsai SY, You DL, Ko JS, Lu MC, Feng AC: Sex-associated differences in non-small cell lung cancer in the new era: is gender an independent prognostic factor? Lung Cancer; 2009 Nov;66(2):262-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sex-associated differences in non-small cell lung cancer in the new era: is gender an independent prognostic factor?
  • BACKGROUND: Women with non-small cell lung cancer (NSCLC) appear to have better survival.
  • Demographics, histology, and disease stage between sexes were compared.
  • The clinical prognostic factors to be analyzed in addition to gender included stage, age, smoking history and histology.
  • RESULTS: Of the 738 patients, 695 were analyzed with a definite stage (94.2%; 315 females and 380 males), which was similar in both sexes.
  • Females were younger (median age: 59.5 years vs. 65.0 years; P<0.001) and more likely to have adenocarcinoma (81% vs. 60.5%; P<0.001).
  • Patients with earlier stage, younger patients, never-smokers and females had better overall survival in univariate analyses and no significant survival difference was noted between adenocarcinoma and squamous cell carcinoma.
  • Subgroup analyses revealed the survival of never-smoker males with adenocarcinoma was similar to that of females.
  • Never-smokers with adenocarcinoma should be given special attention regardless of sex as they imply better survival with different treatment outcomes.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / mortality. Lung Neoplasms / mortality
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / mortality. Adenocarcinoma, Bronchiolo-Alveolar / diagnosis. Aged. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / mortality. Female. Humans. Male. Middle Aged. Prognosis. Sex Factors. Smoking


70. Szczepulska-Wójcik E, Langfort R, Roszkowski-Sliz K: [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation]. Pneumonol Alergol Pol; 2007;75(1):57-69
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The objective of this study was to evaluate the significance of selected immunohistochemical stains in differentiating MM from non-small cell lung cancers infiltrating the pleura and from benign reactive mesothelial cell proliferation.
  • It included broad-spectrum antibodies to cytokeratins (CKAE1/AE3, CKMNF116), vimentin, epithelial membrane antigen (EMA), mesothelial cells (HBME1, CK5/6, calretinin), adenocarcinoma cells (BerEp4, B72.3, CEA, TTF1), antibodies enabling the assessment of proliferation (Mib1) and cell-cycle regulating proteins (p53).
  • Non-small cell lung cancers infiltrating the pleura: Coexpression of cytokeratin and vimentin was found in 17.6% of the cases, positive staining of membranes for EMA, in 13% cases.
  • CONCLUSION: In diagnosing mesothelioma it is necessary to use a panel of immunohistochemical stains, which should contain antibodies to markers for adenocarcinoma and mesothelioma.
  • Due to the high costs of such a study, a two-stage method is advantageous.
  • [MeSH-major] Antigens, Tumor-Associated, Carbohydrate / analysis. Biomarkers, Tumor / analysis. Carcinoma, Non-Small-Cell Lung / pathology. Mesothelioma / pathology. Neoplasm Proteins / analysis. Neoplasms, Mesothelial / pathology. Pleural Neoplasms / pathology
  • [MeSH-minor] Aged. Antibodies, Monoclonal / analysis. Diagnosis, Differential. Epithelium / chemistry. Epithelium / pathology. Female. Humans. Hyperplasia / pathology. Immunohistochemistry. Lung / chemistry. Lung / pathology. Male. Middle Aged. Pleura / chemistry. Pleura / pathology. Pleural Effusion / chemistry. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17541913.001).
  • [ISSN] 0867-7077
  • [Journal-full-title] Pneumonologia i alergologia polska
  • [ISO-abbreviation] Pneumonol Alergol Pol
  • [Language] pol
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


71. Ichinose J, Kohno T, Fujimori S, Mun M: Locoregional control of thoracoscopic lobectomy with selective lymphadenectomy for lung cancer. Ann Thorac Surg; 2010 Jul;90(1):235-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Locoregional control of thoracoscopic lobectomy with selective lymphadenectomy for lung cancer.
  • BACKGROUND: In this retrospective study, we review our experience with video-assisted thoracic surgery (VATS) lobectomy with selective lymphadenectomy for clinical stage I lung cancer and report the long-term results.
  • METHODS: From April 1999 to December 2006, 355 patients with clinical stage I lung cancer underwent a VATS lobectomy.
  • The perioperative data, morbidity, mortality, and long-term survival of each patient were reviewed.
  • CONCLUSIONS: Our findings suggest that performing VATS lobectomy with selective lymphadenectomy for clinical stage I lung cancer is safe and results in acceptable locoregional control.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Lung Neoplasms / pathology. Lung Neoplasms / surgery. Thoracic Surgery, Video-Assisted

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20609783.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


72. Kawaguchi T, Matsumura A, Fukai S, Tamura A, Saito R, Zell JA, Maruyama Y, Ziogas A, Kawahara M, Ignatius Ou SH: Japanese ethnicity compared with Caucasian ethnicity and never-smoking status are independent favorable prognostic factors for overall survival in non-small cell lung cancer: a collaborative epidemiologic study of the National Hospital Organization Study Group for Lung Cancer (NHSGLC) in Japan and a Southern California Regional Cancer Registry databases. J Thorac Oncol; 2010 Jul;5(7):1001-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Japanese ethnicity compared with Caucasian ethnicity and never-smoking status are independent favorable prognostic factors for overall survival in non-small cell lung cancer: a collaborative epidemiologic study of the National Hospital Organization Study Group for Lung Cancer (NHSGLC) in Japan and a Southern California Regional Cancer Registry databases.
  • BACKGROUND: We previously reported that Asian ethnicity was a favorable prognostic factor for overall survival (OS) in non-small cell lung cancer (NSCLC).
  • METHODS: Retrospective population-based analysis of Japanese and Caucasian patients with NSCLC with known smoking status from the Japanese National Hospital Organization Study Group for Lung Cancer and a Southern California Regional Cancer Registry between 1991 and 2001.
  • Univariate analysis revealed Japanese patients with stage III (versus Caucasian; hazard ratio [HR] = 0.830, 95% confidence interval [CI]: 0.789-0.873, p < 0.0001) and IV disease (versus Caucasian; HR = 0.955, 95% CI: 0.915-0.997, p = 0.0369) had improved OS compared with Caucasian patients.
  • Multivariate analysis revealed Japanese ethnicity (versus Caucasian; HR = 0.937, 95% CI: 0.898-0.978, p = 0.0028) and never-smoker status (versus ever-smoker; HR = 0.947, 95% CI: 0.909-0.987, p = 0.0104) to be independent favorable factors for OS in addition to younger age, female gender, early stage, and treatment received (surgery, radiation, and chemotherapy).
  • [MeSH-major] Adenocarcinoma / ethnology. Asian Continental Ancestry Group / ethnology. Carcinoma, Large Cell / ethnology. Carcinoma, Non-Small-Cell Lung / ethnology. European Continental Ancestry Group / ethnology. Lung Neoplasms / ethnology. Neoplasms, Squamous Cell / ethnology

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20526205.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Grant] United States / NCCDPHP CDC HHS / DP / 1U58DP00807-01; United States / NCI NIH HHS / PC / N01-PC-35136; United States / NCI NIH HHS / PC / N01-PC-35139; United States / NCI NIH HHS / PC / N01-PC-54404
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


73. Ikeda N, Hayashi A, Miura Y, Okunaka T, Okuzawa K, Tsuboi M, Kato Y, Suga Y, Kato H: Present strategy of lung cancer screening and surgical management. Ann Thorac Cardiovasc Surg; 2005 Dec;11(6):363-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Present strategy of lung cancer screening and surgical management.
  • Previous lung cancer screening trials in the United States (US) employing chest X ray and sputum cytology did not demonstrate reductions in lung cancer mortality.
  • However, recent case control studies in Japan demonstrated a decrease in lung cancer mortality in the computed tomography (CT) screened group.
  • Lung cancer screening using chest CT detected more cancers at an earlier stage than chest X ray.
  • Before CT screening is widely performed, lung cancer mortality reduction should be proved in a scientific manner.
  • The subtypes of adenocarcinoma; bronchioloalveolar carcinoma (BAC) tends to show specific CT findings called ground glass opacity (GGO) and a favorable prognosis can be expected.
  • Recent studies have shown the proportion of GGO is strongly related to biological malignancy of small adenocarcinoma.
  • Lung cancer researchers are interested in evaluating the nature of small adenocarcinoma as well as the carcinogenic process.
  • [MeSH-major] Lung Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Humans. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16401983.001).
  • [ISSN] 1341-1098
  • [Journal-full-title] Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia
  • [ISO-abbreviation] Ann Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 31
  •  go-up   go-down


74. Grimminger PP, Schneider PM, Metzger R, Vallböhmer D, Danenberg KD, Danenberg PV, Hölscher AH, Brabender J: The prognostic role of Bcl-2 mRNA expression in curatively resected non-small cell lung cancer (NSCLC). Lung Cancer; 2010 Oct;70(1):82-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prognostic role of Bcl-2 mRNA expression in curatively resected non-small cell lung cancer (NSCLC).
  • 45 of the 91 patients had stage I tumors (49%), 19 had stage II (21%) and 27 had stage IIIa (30%).
  • Squamous cell carcinoma was found in 43 patients (47%), adenocarcinoma in 33 (36%) and in large cell carcinoma in 15 (17%) of the patients.
  • RESULTS: Bcl-2 mRNA expression was detected in 83 (91%) of the investigated tumor samples and in 74 (81%) of the normal lung tissue.
  • The median gene expression was 0.147 in tumor tissue and 0.144 in matching normal lung tissue (p=n.s., Wilcoxon Test).
  • No associations were seen between the tumorous Bcl-2 mRNA expression levels and clinical or histopathologic parameters such as gender, tumor size, TNM stadium and grading, but with tumor histology and smoking.
  • Multivariate regression analysis revealed Bcl-2 expression status and tumor stage as independent prognostic factor.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Carcinoma, Non-Small-Cell Lung / metabolism. Lung Neoplasms / metabolism. Proto-Oncogene Proteins c-bcl-2 / biosynthesis

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20064672.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Messenger
  •  go-up   go-down


75. Byun JH, Lee MA, Roh SY, Shim BY, Hong SH, Ko YH, Ko SJ, Woo IS, Kang JH, Hong YS, Lee KS, Lee AW, Park GS, Lee KY: Association between cyclooxygenase-2 and matrix metalloproteinase-2 expression in non-small cell lung cancer. Jpn J Clin Oncol; 2006 May;36(5):263-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association between cyclooxygenase-2 and matrix metalloproteinase-2 expression in non-small cell lung cancer.
  • This study aims to assess the correlation of the COX-2 expression and the MMP-2 expression in patients with non-small cell lung cancer (NSCLC).
  • Furthermore, the MMP-2 expression was associated with lymph node involvement, the tumor stage and the histological type.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / enzymology. Cyclooxygenase 2 / biosynthesis. Lung Neoplasms / enzymology. Matrix Metalloproteinase 2 / biosynthesis
  • [MeSH-minor] Adenocarcinoma / enzymology. Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Carcinoma, Large Cell / enzymology. Carcinoma, Large Cell / pathology. Carcinoma, Squamous Cell / enzymology. Carcinoma, Squamous Cell / pathology. Female. Humans. Immunohistochemistry. Isoenzymes / biosynthesis. Male. Middle Aged. Neoplasm Staging. Survival Analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16735371.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Isoenzymes; EC 1.14.99.1 / Cyclooxygenase 2; EC 3.4.24.24 / Matrix Metalloproteinase 2
  •  go-up   go-down


76. Chua TS, Sng C, Chatterjee D, Poh WT: Clinical usefulness of endoscopic ultrasonography-guided fine-needle aspiration in the diagnosis and staging of lung cancer. Singapore Med J; 2007 May;48(5):460-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical usefulness of endoscopic ultrasonography-guided fine-needle aspiration in the diagnosis and staging of lung cancer.
  • Lung cancer is the most common cause of cancer-related mortality in Singapore, and accurate staging of lung cancer is therefore of paramount importance.
  • Several non-invasive and invasive modalities can be used to stage lung cancer.
  • We present three cases in which EUS-FNA was used successfully to diagnose and stage lung cancer, thus avoiding surgery.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biopsy, Fine-Needle. Endosonography. Lung Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17453105.001).
  • [ISSN] 0037-5675
  • [Journal-full-title] Singapore medical journal
  • [ISO-abbreviation] Singapore Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


77. Bae NC, Chae MH, Lee MH, Kim KM, Lee EB, Kim CH, Park TI, Han SB, Jheon S, Jung TH, Park JY: EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients. Cancer Genet Cytogenet; 2007 Mar;173(2):107-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients.
  • The epidermal growth factor receptor (EGFR), and its family members play an important role in the development and progression of lung cancers.
  • It has been reported that somatic mutations in the tyrosine kinase domain of the EGFR or ERBB2 genes occur in a subset of patients with lung cancer.
  • We searched for mutations of the EGFR, ERBB2, and KRAS genes in surgically resected non-small cell lung cancers (NSCLCs) to determine the prevalence of these mutations in Korean lung cancer patients.
  • In addition, we examined the relationship between the mutations and clinicopathologic features of lung cancers.
  • Mutations of the EGFR, ERBB2, and KRAS genes were determined by polymerase chain reaction-based direct sequencing in 115 surgically resected non-small cell lung cancers.
  • The ERBB2 mutation was found in 1 adenocarcinoma of the 115 NSCLCs (0.9% overall; 1.8% of the 55 adenocarcinomas).
  • EGFR mutations in adenocarcinomas were not associated with pathologic stage in never-smokers, but were more frequent in pathologic stage II-IV than in stage I in ever-smokers (P = 0.01).
  • These findings suggest that the EGFR mutation is frequent in Korean lung cancer patients, and that the ERBB2 mutation is rare.
  • Further studies are needed to investigate the role of EGFR mutations in the carcinogenesis of adenocarcinoma among smokers.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. Genes, ras / genetics. Lung Neoplasms / genetics. Mutation. Receptor, Epidermal Growth Factor / genetics. Receptor, ErbB-2 / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Adult. Aged. Base Sequence. Chi-Square Distribution. DNA Mutational Analysis. Female. Humans. Korea. Logistic Models. Male. Middle Aged. Neoplasm Staging. Smoking


78. Chen X, Zhao J, Guan YH, Lu S, Zuo CT, Hua FC, Lin X: Prognostic value of 2-[18F]fluoro-2-deoxy-D-glucose uptake as measured by PET scan in patients with non-small cell lung cancer. Mol Med Rep; 2008 Nov-Dec;1(6):889-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of 2-[18F]fluoro-2-deoxy-D-glucose uptake as measured by PET scan in patients with non-small cell lung cancer.
  • This study aimed to evaluate the prognostic value of 2-[18F]fluoro-2-deoxy-D-glucose (18F-FDG) uptake determined by positron emission tomography (PET) in patients with non-small cell lung cancer (NSCLC) in relation to disease stage and/or tumor histology.
  • A retrospective review of 144 patients with newly diagnosed lung cancer undergoing PET imaging was performed.
  • Univariate analysis identified three prognostic factors: stage, lesion size and the standardized 18F-FDG uptake value.
  • The latter was a better prognostic predictor in lung cancer patients with early-stage disease than in those at advanced stages.
  • Multivariate analysis revealed that the most important prognostic factors were tumor-node-metastasis (TNM) stage and the standardized 18F-FDG uptake value.
  • SUVs provided stronger prognostic stratification in patients with adenocarcinoma than in those with squamous cell carcinoma (SCC).
  • Furthermore, the best choice of prognostic predictor differed between the two types of lung cancer: the SUV was best for SCC, while TNM stage was most significant for adenocarcinoma.
  • In conclusion, 18F-FDG uptake in primary lung lesions is an independent prognostic predictor in patients with NSCLC, especially those with adenocarcinoma or early-stage disease.
  • Further stratification of patients with the same TNM stage based on SUVs may allow for the modification of individual treatment strategies, resulting in improved outcome.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21479502.001).
  • [ISSN] 1791-2997
  • [Journal-full-title] Molecular medicine reports
  • [ISO-abbreviation] Mol Med Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


79. Ak G, Metintas M, Metintas S, Yildirim H, Erginel S, Alatas F: Lung cancer in individuals less than 50 years of age. Lung; 2007 Sep-Oct;185(5):279-286
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung cancer in individuals less than 50 years of age.
  • The aim of this study was to compare the epidemiologic, clinical, and laboratory characteristics and survival rates of younger and older patients with lung cancer.
  • We studied 1340 patients who were histopathologically diagnosed as having lung cancer from 1990 to 2005.
  • In the younger group, exposure to occupational risk factors was a risk factor for lung cancer, while in the older group, smoking was a risk factor.
  • The incidence of adenocarcinoma and small-cell carcinoma was greater in the younger group, while squamous cell carcinoma was more common in the older group.
  • Metastasis rates were significantly different between the two age groups: 52.0% of the younger group presented with stage IV disease compared with 43.5% of the older group.
  • These data indicate that lung cancer had different etiopathogenetic characteristics in younger patients, which may have clinical implications.
  • [MeSH-major] Adenocarcinoma / epidemiology. Carcinoma, Small Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Lung Neoplasms / epidemiology

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chest. 1999 May;115(5):1232-6 [10334132.001]
  • [Cites] Cancer. 1991 Mar 1;67(5):1436-8 [1991310.001]
  • [Cites] Am J Ind Med. 1989;15(5):565-78 [2741962.001]
  • [Cites] Chest. 2000 Feb;117(2):354-7 [10669674.001]
  • [Cites] Cancer Detect Prev. 1994;18(5):349-55 [7812981.001]
  • [Cites] Am Rev Respir Dis. 1986 Sep;134(3):466-70 [3752703.001]
  • [Cites] Chest. 1992 Dec;102(6):1723-9 [1446479.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):651-7 [9469354.001]
  • [Cites] Chest. 1993 Nov;104(5):1477-81 [8222810.001]
  • [Cites] Cancer. 1999 Apr 15;85(8):1730-3 [10223566.001]
  • [Cites] J Surg Oncol. 2001 Jul;77(3):208-12 [11455559.001]
  • [Cites] Respir Med. 1992 Nov;86(6):499-502 [1335158.001]
  • [Cites] Chest. 1997 Jun;111(6):1710-7 [9187198.001]
  • [Cites] Chest. 2001 Jul;120(1):32-6 [11451812.001]
  • [Cites] Chest. 1989 Dec;96(6):1298-301 [2555113.001]
  • [Cites] Chest. 1985 Apr;87(4):456-9 [2983952.001]
  • [Cites] Am J Public Health. 1987 Apr;77(4):425-31 [3826460.001]
  • [Cites] Respirology. 2001 Dec;6(4):293-6 [11844119.001]
  • [Cites] Lung Cancer. 2001 Aug-Sep;33(2-3):203-11 [11551415.001]
  • [Cites] J Clin Oncol. 1994 May;12(5):981-5 [8164051.001]
  • [Cites] Anticancer Res. 2006 Jul-Aug;26(4B):3175-81 [16886653.001]
  • [Cites] Lung Cancer. 2001 Jun;32(3):255-64 [11390007.001]
  • (PMID = 17705064.001).
  • [ISSN] 0341-2040
  • [Journal-full-title] Lung
  • [ISO-abbreviation] Lung
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Germain F, Wai ES, Berthelet E, Truong PT, Lesperance M: Brain metastasis is an early manifestation of distant failure in stage III nonsmall cell lung cancer patients treated with radical chemoradiation therapy. Am J Clin Oncol; 2008 Dec;31(6):561-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain metastasis is an early manifestation of distant failure in stage III nonsmall cell lung cancer patients treated with radical chemoradiation therapy.
  • OBJECTIVES: To evaluate the patterns of distant relapse, focusing on brain metastasis, in patients with stage III nonsmall cell lung cancer (NSCLC) treated with radical chemoradiation therapy (CRT).
  • METHODS: The British Columbia Cancer Agency provincial database identified 2268 patients presenting with stage III NSCLC between January 1, 1990 and December 31, 2000.
  • Variables analyzed included gender, age, Eastern Cooperative Oncology Group performance status, stage, histology, sites of metastasis, and survival.
  • There were 74 stage IIIA and 46 stage IIIB cases.
  • Histologic subtypes were squamous cell carcinoma (n = 29), adenocarcinoma (n = 53), and other non-squamous histologies (n = 38).
  • CONCLUSIONS: Stage III NSCLC patients treated with CRT have high risks of brain metastasis which persist during the first 10 months after diagnosis.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / therapy. Carcinoma, Squamous Cell / therapy. Lung Neoplasms / therapy. Neoplasm Recurrence, Local / diagnosis


81. Yeo SG, Cho MJ, Kim SY, Lim SP, Kim KH, Kim JS: Treatment outcomes of three-dimensional conformal radiotherapy for stage III non-small cell lung cancer. Cancer Res Treat; 2005 Oct;37(5):273-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment outcomes of three-dimensional conformal radiotherapy for stage III non-small cell lung cancer.
  • PURPOSE: To evaluate the treatment outcomes of the three-dimensional conformal radiotherapy (3D-CRT), in conjunction with induction chemotherapy, for the treatment of stage III non-small cell lung cancer (NSCLC).
  • MATERIALS AND METHODS: Between November 1998 and March 2003, 22 patients with histologically proven, clinical stage III NSCLC, treated with induction chemotherapy, followed by 3D-CRT, were retrospectively analyzed.
  • The histologies were squamous cell carcinoma, adenocarcinoma and others in 73, 18 and 9%, respectively.
  • The prognostic factors for overall survival by a univariate analysis were age, histology and T stage (p<0.05).
  • Acute radiation toxicities, as evaluated by the RTOG toxicity criteria, included two cases of grade 3 lung toxicity and one case of grade 2 esophagus toxicity.
  • It also seems to be a safe, well-tolerated and effective treatment modality for stage III NSCLC.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):681-5 [11395236.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Sep 1;45(2):323-9 [10487552.001]
  • [Cites] J Natl Cancer Inst. 1996 Sep 4;88(17):1210-5 [8780630.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Dec 1;33(5):1001-7 [7493826.001]
  • [Cites] BMJ. 1995 Oct 7;311(7010):899-909 [7580546.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Oct 20;27(3):493-8 [8226140.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Sep 30;27(2):273-84 [8407401.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(2):367-75 [1587758.001]
  • [Cites] J Natl Cancer Inst. 1991 Mar 20;83(6):417-23 [1847977.001]
  • [Cites] Cancer. 1987 Jun 1;59(11):1874-81 [3032394.001]
  • [Cites] N Engl J Med. 1990 Oct 4;323(14):940-5 [2169587.001]
  • [Cites] J Clin Oncol. 1990 Sep;8(9):1543-55 [2167952.001]
  • [Cites] Cancer. 1980 Jun 1;45(11):2744-53 [6991092.001]
  • [Cites] J Clin Oncol. 2004 Nov 1;22(21):4341-50 [15514375.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):419-26 [15380575.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Dec 1;57(5):1437-42 [14630283.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Nov 15;54(4):999-1006 [12419425.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Jan 1;52(1):49-57 [11777621.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Nov 1;51(3):660-5 [11597806.001]
  • [Cites] Radiother Oncol. 1997 Jul;44(1):17-22 [9288852.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1079-85 [9169816.001]
  • (PMID = 19956526.001).
  • [ISSN] 2005-9256
  • [Journal-full-title] Cancer research and treatment : official journal of Korean Cancer Association
  • [ISO-abbreviation] Cancer Res Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2785930
  • [Keywords] NOTNLM ; Chemoradiotherapy / Conformal radiotherapy / Non-small cell lung carcinoma
  •  go-up   go-down


82. Thibout Y, Guibert B, Bossard N, Tronc F, Tiffet O, de la Roche E, Mulsant P, Gamondes JP, Baulieux J, Remontet L, Geriniere L, Souquet PJ: Is pneumonectomy after induction chemotherapy for non-small cell lung cancer a reasonable procedure? A multicenter retrospective study of 228 cases. J Thorac Oncol; 2009 Dec;4(12):1496-503
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is pneumonectomy after induction chemotherapy for non-small cell lung cancer a reasonable procedure? A multicenter retrospective study of 228 cases.
  • INTRODUCTION: Pneumonectomy (PN) after induction chemotherapy (CT) for non-small cell lung cancer is controversial because high-mortality rates are still reported.
  • Postoperative mortality and morbidity and long-term outcomes were studied.
  • The independent risk factors identified for operative mortality were chronic obstructive pulmonary disease, manual suture of the stump, and pTNM stage higher than IIIA.
  • CONCLUSIONS: Induction CT was not found to compromise short- or long-term outcomes after PN in non-small cell lung cancer.
  • [MeSH-major] Adenocarcinoma / surgery. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Large Cell / surgery. Carcinoma, Non-Small-Cell Lung / surgery. Carcinoma, Squamous Cell / surgery. Lung Neoplasms / surgery. Pneumonectomy

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19745768.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 5V9KLZ54CY / Vinblastine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


83. Lees AN, Reid DW: Management dilemma; a woman with cystic fibrosis and severe lung disease presenting with colonic carcinoma: a case report. J Med Case Rep; 2008;2:384
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management dilemma; a woman with cystic fibrosis and severe lung disease presenting with colonic carcinoma: a case report.
  • Individuals with cystic fibrosis who have advanced lung disease present a high operative risk, limiting curative treatment options in early bowel malignancy.
  • CASE PRESENTATION: We describe a 41-year-old Caucasian woman with cystic fibrosis and severe lung disease who had been considered for lung transplantation, who presented with rectal bleeding and was found to have a Stage I adenocarcinoma of the sigmoid colon.
  • CONCLUSION: We discuss the complexity of the management decisions for cystic fibrosis patients with severe lung disease and early stage colonic malignancy, particularly in the context of potential need for lung transplantation.
  • The case demonstrates that cystic fibrosis patients with very severe lung function impairment may undergo laparoscopic abdominal surgical interventions without compromising postoperative airway clearance.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cyst Fibros. 2008 Sep;7(5):343-6 [18374636.001]
  • [Cites] Mol Cell Biochem. 2008 Sep;316(1-2):169-75 [18604476.001]
  • [Cites] J Cyst Fibros. 2008 Jan;7(1):1-6 [17766191.001]
  • [Cites] Transpl Int. 2007 Jun;20(6):497-504 [17343685.001]
  • [Cites] Int J Colorectal Dis. 2005 Mar;20(2):147-54 [15592853.001]
  • [Cites] Dis Colon Rectum. 2004 Nov;47(11):1898-903 [15622583.001]
  • [Cites] Can J Gastroenterol. 1996 Nov-Dec;10(7):440-2 [9113885.001]
  • [Cites] N Engl J Med. 1995 Feb 23;332(8):494-9 [7830730.001]
  • (PMID = 19077322.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2615444
  •  go-up   go-down


84. Endo S, Tsubochi H, Nakano T, Miwa C, Watanabe K, Koyama S, Sohara Y: [Video-assisted thoracoscopic left upper lobectomy for lung cancer patients: bronchial dissection technique prior to pulmonary artery dissection]. Kyobu Geka; 2008 Feb;61(2):122-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Video-assisted thoracoscopic left upper lobectomy for lung cancer patients: bronchial dissection technique prior to pulmonary artery dissection].
  • PATIENTS AND TECHNIQUE: Between August 2006 and July 2007, 12 patients with clinical stage IA-lung cancer underwent the video-assisted thoracoscopic left upper lobectomy with bronchial dissection prior to anterior and apico-posterior pulmonary artery dissections following dissection of lingular segmental artery.
  • [MeSH-major] Adenocarcinoma / surgery. Bronchi / surgery. Lung Neoplasms / surgery. Pneumonectomy / methods. Pulmonary Artery / surgery. Thoracic Surgery, Video-Assisted / methods

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18268948.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


85. Liu H, Zhang T, Li X, Huang J, Wu B, Huang X, Zhou Y, Zhu J, Hou J: Predictive value of MMP-7 expression for response to chemotherapy and survival in patients with non-small cell lung cancer. Cancer Sci; 2008 Nov;99(11):2185-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictive value of MMP-7 expression for response to chemotherapy and survival in patients with non-small cell lung cancer.
  • The present study assessed the prognostic and predictive value of MMP-7 in tumors of patients with advanced non-small cell lung cancer (NSCLC) treated with platinum-based chemotherapy.
  • In total, 159 patients with stage III and IV NSCLC were retrospectively enrolled.
  • MMP-7 status was correlated inversely with response to chemotherapy in overall patients (response rates, 20.0% and 35.8%, for patients with high-MMP-7 and low-MMP-7 tumors, respectively, P = 0.036), especially in adenocarcinoma (P = 0.021), but not in patients with squamous cell carcinomas (P = 0.373).
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / mortality. Lung Neoplasms / drug therapy. Lung Neoplasms / mortality. Matrix Metalloproteinase 7 / metabolism
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disease-Free Survival. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies


86. Kageyama S, Narita M, Kim CJ, Hanada E, Sakano Y, Iwaki H, Yoshiki T, Okada Y: [Small cell carcinoma of the prostate: a report of three patients and a prognostic analysis of cases reported in Japan]. Hinyokika Kiyo; 2006 Oct;52(10):809-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Case 2: A 65-year-old man presented with pure prostatic SCC with lung metastases.
  • Case 3: A 73-year-old man was diagnosed as having SCC and poorly differentiated adenocarcinoma of the prostate simultaneously.
  • Many patients had lymph node or distant metastases (stage D, 73%).
  • Thirty-seven (45%) were pure SCCs and 45 (55%) were associated with adenocarcinoma.
  • The prognosis after the recognition of SCC is very poor, and the 1- and 2-year survival rates were 27% and 10%, respectively.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17131874.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


87. Ren SH, Wang JW, Zhang L: [Effects of Her-2/neu siRNA-mediated gene silencing on cell cycle and apoptosis of lung adenocarcinoma cells]. Zhonghua Yi Xue Za Zhi; 2005 Jun 15;85(22):1530-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effects of Her-2/neu siRNA-mediated gene silencing on cell cycle and apoptosis of lung adenocarcinoma cells].
  • OBJECTIVE: To investigate the effect of synthesized Her-2/neu specific siRNA on the cell cycle and apoptosis of Her-2/neu upregulating human lung adenocarcinoma cells.
  • METHODS: Human lung cancer cells of the line calu-3 were cultured and divided into 4 groups: untreated control group, blank vector group transfected with blank vector, non-specific siRNA group transfected with unrelated siRNA, and Her2/neu siRNA group transfected with Her2/neu siRNA.
  • Forty-eight hours after transfection, the expression rate of Her-2/neu protein was 25.0% +/- 1.6% in the calu-3 cells transfected with Her-2/neu siRNA, significantly lower than in the control group, blank vector group, and non-specific siRNA group (98.2% +/- 2.2%, 95.7% +/- 2.0%, and 94.8% +/- 1.6% respectively, all P < 0.01); the proportion of the cells in G(0)/G(1) stage increased and those in the S stage decreased in the celu-3 cells transfected with Her-2/neu siRNA, and the proportions of the cells in G(0)/G(1) stage and Stage did not significantly change (F = 6.1, P < 0.01); the apoptotic rate of the Her2/neu siRNA group was 25.1% +/- 1.2%, significantly higher than those of the other 3 groups (4.8% +/- 0.5%, 8.6% +/- 0.9%, and 10.3% +/- 0.3% respectively, all P < 0.01); the caspase-3 activity ratio of the Her2/neu siRNA group was 134.6% +/- 4.5%, significantly higher than those in the blank vector group and non-specific siRNA group (105.0% +/- 2.5% and 112.0% +/- 2.8% respectively, both P < 0.01), and the VEGF level in the supernatant of the Her2/neu siRNA group was 176 pg/ml +/- 6 pg/ml, significantly lower than those of the control group, blank vector group, and non-specific siRNA group (476 pg/ml +/- 13 pg/ml, 426 pg/ml +/- 9 pg/ml, and 406 pg/ml +/- 9 pg/ml respectively, all P < 0.01).
  • CONCLUSION: Chemically synthesized Specific Her-2/neu targeting siRNA effectively inhibits Her-2/neu expression and leads to the decline of cyclin D(1) and VEGF levels and activation of caspase-3 pathway thus arresting the cell cycle at G(0)/G(1) stage and enhancing cell apoptosis.
  • [MeSH-major] Adenocarcinoma / pathology. Apoptosis / physiology. Gene Silencing. Lung Neoplasms / pathology. Receptor, ErbB-2 / biosynthesis


88. Reyes-Gibby CC, Shete S, Yennurajalingam S, Frazier M, Bruera E, Kurzrock R, Crane CH, Abbruzzese J, Evans D, Spitz MR: Genetic and nongenetic covariates of pain severity in patients with adenocarcinoma of the pancreas: assessing the influence of cytokine genes. J Pain Symptom Manage; 2009 Dec;38(6):894-902
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic and nongenetic covariates of pain severity in patients with adenocarcinoma of the pancreas: assessing the influence of cytokine genes.
  • We previously demonstrated that select cytokine gene polymorphisms in interleukin (IL)-8 are a significant predictor of pain and analgesia in patients with lung cancer.
  • We evaluated a series of patients with histologically confirmed adenocarcinoma of the pancreas (n=484), who had completed a self-administered survey of pain before initiating any cancer treatment.
  • Severe pain varied by the stage of disease (odds ratio [OR] Stage II=4.02, 95% confidence interval (CI)=1.07, 15.07; Stage III=5.02, 95% CI=1.28, 19.61; Stage IV=6.90, 95% CI=1.96, 24.29), ethnicity (OR non-Hispanic blacks=3.67; 95% CI=1.44, 9.38), reports of depressed mood (OR=1.94; 95% CI=1.09, 3.43), and female sex (OR=1.78; 95% CI=1.04, 3.05).

  • MedlinePlus Health Information. consumer health - Pain.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2007 Jun 7;447(7145):655-60 [17554299.001]
  • [Cites] Cancer. 2004 Dec 15;101(12):2727-36 [15526319.001]
  • [Cites] Lancet Oncol. 2008 Aug;9(8):777-85 [18672213.001]
  • [Cites] J Intern Med. 2005 Feb;257(2):139-55 [15656873.001]
  • [Cites] Eur J Pharmacol. 2000 Jan 3;387(1):111-8 [10633169.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Feb 1;102(5):1755-60 [15665080.001]
  • [Cites] Behav Brain Res. 2006 Feb 28;167(2):355-64 [16256210.001]
  • [Cites] Head Neck. 2006 Apr;28(4):313-20 [16200627.001]
  • [Cites] Neurosci Lett. 2006 Aug 14;404(1-2):154-8 [16777324.001]
  • [Cites] Pain. 2006 Dec 15;126(1-3):294-308 [16949747.001]
  • [Cites] Urology. 2000 Dec 20;56(6):899-905 [11113727.001]
  • [Cites] Oncology (Williston Park). 2000 Nov;14(11A):135-50 [11195407.001]
  • [Cites] J Neurosci. 2001 Jul 15;21(14):5027-35 [11438578.001]
  • [Cites] Eur Spine J. 2002 Feb;11(1):62-6 [11931066.001]
  • [Cites] Adv Exp Med Biol. 2003;521:1-21 [12617561.001]
  • [Cites] Am J Med Genet B Neuropsychiatr Genet. 2004 Jan 1;124B(1):50-3 [14681913.001]
  • [Cites] Am J Med. 2004 Mar 1;116(5):318-24 [14984817.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 17;96(6):434-42 [15026468.001]
  • [Cites] Qual Life Res. 2004 Oct;13(8):1369-79 [15503832.001]
  • [Cites] Brain Res. 1994 Aug 15;654(1):15-26 [7982088.001]
  • [Cites] Life Sci. 1995;57(11):1011-26 [7658909.001]
  • [Cites] Med Care. 1996 Mar;34(3):220-33 [8628042.001]
  • [Cites] Pain. 1995 Dec;63(3):289-302 [8719529.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jul 6;96(14):7710-3 [10393885.001]
  • [Cites] Pain. 1999 Sep;82(3):263-74 [10488677.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Dec;16(12):2745-51 [18086782.001]
  • (PMID = 19692203.001).
  • [ISSN] 1873-6513
  • [Journal-full-title] Journal of pain and symptom management
  • [ISO-abbreviation] J Pain Symptom Manage
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R03 CA128069; United States / NCI NIH HHS / CA / R03 CA128069-01A2; United States / NCI NIH HHS / CA / CA128069-01A2; United States / NCI NIH HHS / CA / K07 CA109043-05; United States / NCI NIH HHS / CA / CA109043-05; United States / NCI NIH HHS / CA / K07 CA109043; United States / NCI NIH HHS / CA / CA128069; United States / NCI NIH HHS / CA / P20 CA101936; United States / NCI NIH HHS / CA / CA101936; United States / NCI NIH HHS / CA / CA109043
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Analgesics; 0 / Cytokines
  • [Other-IDs] NLM/ NIHMS131146; NLM/ PMC2795073
  •  go-up   go-down


89. Liptay MJ, D'amico TA, Nwogu C, Demmy TL, Wang XF, Gu L, Litle VR, Swanson SJ, Kohman LJ, Thoracic Surgery Subcommittee of the Cancer and Leukemia Group B: Intraoperative sentinel node mapping with technitium-99 in lung cancer: results of CALGB 140203 multicenter phase II trial. J Thorac Oncol; 2009 Feb;4(2):198-202
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative sentinel node mapping with technitium-99 in lung cancer: results of CALGB 140203 multicenter phase II trial.
  • INTRODUCTION: Sentinel node mapping with radioactive technetium in non-small cell lung cancer has been shown to be feasible in several single institution reports.
  • METHODS: Patients with clinical stage I non-small cell lung cancer amenable to resection were candidates for this trial.
  • CONCLUSIONS: Intraoperative sentinel node mapping in lung cancer with radioisotope yielded lower accrual and worse accuracy than expected.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / secondary. Lung Neoplasms / pathology. Lymph Nodes / radionuclide imaging. Monitoring, Intraoperative. Radiopharmaceuticals. Technetium Tc 99m Sulfur Colloid
  • [MeSH-minor] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Aged. Aged, 80 and over. Carcinoma, Large Cell / secondary. Carcinoma, Large Cell / surgery. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / surgery. Feasibility Studies. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Prognosis. Risk Factors. Sentinel Lymph Node Biopsy. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19179896.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 556Q0P6PB1 / Technetium Tc 99m Sulfur Colloid
  •  go-up   go-down


90. Takimoto T, Hirashima T, Kobayashi M, Nitta T, Sasada S, Nakamura Y, Matsui K, Kawahara K, Kawase I: Gefitinib for previously untreated patients with non-small cell lung cancer (NSCLC)--a retrospective study of 12 patients treated in one institution. Gan To Kagaku Ryoho; 2005 Nov;32(12):1985-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gefitinib for previously untreated patients with non-small cell lung cancer (NSCLC)--a retrospective study of 12 patients treated in one institution.
  • Gefitinib has a modest activity in previously treated patients with advanced non-small cell lung cancer (NSCLC).
  • The histological types were adenocarcinoma in all patients.
  • Clinical stage was IIB in one patient, IIIB in four, and IV in seven.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Lung Neoplasms / drug therapy. Quinazolines / therapeutic use


91. Kawaguchi Y, Noriyuki T, Kuroda Y, Kuranishi F, Nakahara M, Fukuda T, Ishizaki Y, Hotta R, Akimoto E, Mori H: [Right lung cancer with right aortic arch]. Kyobu Geka; 2008 Feb;61(2):113-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Right lung cancer with right aortic arch].
  • The further examinations revealed the shadow to be primary lung cancer (Rt. S6. adenocarcinoma, cT2N0M0, c-stage IB) with right aortic arch.
  • Since lymph node was found by intraopetrative pathological examination, since no metastasis from interlobar to subcarinal lymph node was found, we did not perform dissection of upper mediastinal dissection, which was equivalent to ND2a lymph nodes dissection of the left lung cancer in General Rule for Clinical and Pathological Record of Lung Cancer.
  • [MeSH-major] Adenocarcinoma / surgery. Aorta, Thoracic / abnormalities. Lung Neoplasms / surgery
  • [MeSH-minor] Angiography. Humans. Imaging, Three-Dimensional. Lung / blood supply. Male. Mediastinum / blood supply. Middle Aged. Pneumonectomy. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18268946.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 8
  •  go-up   go-down


92. Madroszyk-Flandin A, Bagattini S, Gonçalves A, Salem N, Viret F, Viallat JR, Rousseau F, Protière C, Bertucci F, Maraninchi D, Viens P: Lung cancer in elderly patients: a retrospective analysis of practice in a single institution. Crit Rev Oncol Hematol; 2007 Oct;64(1):43-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung cancer in elderly patients: a retrospective analysis of practice in a single institution.
  • Incidence of non-small cell lung cancer is increasing especially among elderly with about 40% arising in patients over 70 years old.
  • Seventy-one patients with lung cancer over 70 years old were treated in Institut Paoli-Calmettes from January 2000 until December 2003 (male/female: 57/14).
  • Histological characteristics: epidermoïd/adenocarcinoma/undifferentiated/small cells: 39.4%/26.8%/15.5%/9.9%.
  • Most of them were advanced lung cancer: St IIIB=14 (19.7%) and St IV=37 (52.1%).
  • The 1-year survival rate was 48.5% and the estimated median survival time was 11 months (95%; 7-18 months) for all patients.
  • The 1-year survival rate was 75% and 21.6% and the estimated median survival time was 25.9 months (95%; 12.6, ND) and 5.7 months (95%; 4.2-9.6) for stage IIIB and IV, respectively.
  • CONCLUSIONS: Chemotherapy is feasible in elderly patients with lung cancer.
  • [MeSH-major] Lung Neoplasms / drug therapy. Lung Neoplasms / epidemiology

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17826629.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


93. Schreiber D, Rineer J, Vongtama D, Wortham A, Han P, Schwartz D, Choi K, Rotman M: Impact of postoperative radiation after esophagectomy for esophageal cancer. J Thorac Oncol; 2010 Feb;5(2):244-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: From 1998 to 2005, patients diagnosed with stage T3-4N0M0 or T1-4N1M0 esophageal adenocarcinoma (AC) or squamous cell carcinoma (SCC) who were definitively treated with esophagectomy, with or without postoperative radiation, were selected.
  • For American Joint Committee on Cancer stage III esophageal carcinoma (T3N1M0 or T4N0-1M0), there was significant improvement in median and 3-year OS (p < 0.001) and DSS (p < 0.001), respectively.
  • CONCLUSIONS: This large population-based review supports the use of postoperative radiation for stage III SCC and AC of the esophagus.


94. Hoikkala S, Pääkkö P, Soini Y, Mäkitaro R, Kinnula V, Turpeenniemi-Hujanen T: Tissue MMP-2 and MMP-9 [corrected] are better prognostic factors than serum MMP-2/TIMP-2--complex or TIMP-1 [corrected] in stage [corrected] I-III lung carcinoma. Cancer Lett; 2006 May 8;236(1):125-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tissue MMP-2 and MMP-9 [corrected] are better prognostic factors than serum MMP-2/TIMP-2--complex or TIMP-1 [corrected] in stage [corrected] I-III lung carcinoma.
  • Here, we investigated the tumor immunoreactive protein of MMP-2, MMP-9 and TIMP-1 as well as the levels of circulating total TIMP-1 and MMP-2/TIMP-2-complex as prognostic factors in lung cancer patients.
  • The material included 59 patients, 30 with a squamous cell carcinoma, 21 with an adenocarcinoma and eight with other histology.
  • In patients with a squamous cell carcinoma Stage I, low serum TIMP-1 (<or=300 ng/ml) also predicted unfavorable survival (log rank P=0.033).
  • We conclude that in lung carcinoma the best prognostic value is achieved by using immunohistochemistry for MMP-2 and MMP-9.
  • [MeSH-major] Adenocarcinoma / enzymology. Biomarkers, Tumor / analysis. Biomarkers, Tumor / blood. Carcinoma, Squamous Cell / enzymology. Lung Neoplasms / enzymology. Matrix Metalloproteinase 2 / analysis. Matrix Metalloproteinase 2 / blood. Tissue Inhibitor of Metalloproteinase-2 / analysis. Tissue Inhibitor of Metalloproteinase-2 / blood

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Cancer Lett. 2007 Mar 18;247(2):359
  • (PMID = 15982804.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tissue Inhibitor of Metalloproteinase-1; 127497-59-0 / Tissue Inhibitor of Metalloproteinase-2; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


95. Grills IS, Fitch DL, Goldstein NS, Yan D, Chmielewski GW, Welsh RJ, Kestin LL: Clinicopathologic analysis of microscopic extension in lung adenocarcinoma: defining clinical target volume for radiotherapy. Int J Radiat Oncol Biol Phys; 2007 Oct 1;69(2):334-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic analysis of microscopic extension in lung adenocarcinoma: defining clinical target volume for radiotherapy.
  • PURPOSE: To determine the gross tumor volume (GTV) to clinical target volume margin for non-small-cell lung cancer treatment planning.
  • METHODS: A total of 35 patients with Stage T1N0 adenocarcinoma underwent wedge resection plus immediate lobectomy.
  • The gross tumor dimensions were measured on a computed tomography (CT) scan (lung and mediastinal windows) and compared with the pathologic dimensions.
  • The potential coverage of microscopic extension for two different lung stereotactic radiotherapy regimens was evaluated.
  • The CT lung windows correlated better with the pathologic size than did the mediastinal windows (gross pathologic size overestimated by a mean of 5.8 mm; composite size [gross plus microscopic extension] underestimated by a mean of 1.2 mm).
  • For a GTV contoured on the CT lung windows, the margin required to cover microscopic extension for 90% of the cases would be 9 mm (9, 7, and 4 mm for Grade 1 to 3, respectively).
  • CONCLUSION: For lung adenocarcinomas, the GTV should be contoured using CT lung windows.
  • Although a GTV based on the CT lung windows would underestimate the gross tumor size plus microscopic extension by only 1.2 mm for the average case, the clinical target volume expansion required to cover the microscopic extension in 90% of cases could be as large as 9 mm, although considerably smaller for high-grade tumors.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Non-Small-Cell Lung / radiography. Lung Neoplasms / pathology. Lung Neoplasms / radiography. Tumor Burden
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / radiography. Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Humans. Radiosurgery. Radiotherapy Dosage. Radiotherapy Planning, Computer-Assisted

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17570609.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


96. Ho JC, Mak JC, Ho SP, Ip MS, Tsang KW, Lam WK, Chan-Yeung M: Manganese superoxide dismutase and catalase genetic polymorphisms, activity levels, and lung cancer risk in Chinese in Hong Kong. J Thorac Oncol; 2006 Sep;1(7):648-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Manganese superoxide dismutase and catalase genetic polymorphisms, activity levels, and lung cancer risk in Chinese in Hong Kong.
  • We investigated the risk of lung cancer development with respect to manganese superoxide dismutase (MnSOD) and catalase genetic polymorphisms and their association with erythrocyte antioxidant activities.
  • PATIENTS AND METHODS: This was a case-control study involving patients with confirmed lung cancer and age-matched healthy controls.
  • RESULTS: We recruited 240 patients with lung cancer (63% male, aged 55.6 +/- 11.9 years, 58% adenocarcinoma, 85% clinical stage III or IV) and 240 age-matched healthy controls.
  • The frequencies of the Val allele of MnSOD gene and the C allele of catalase gene were common (>86% and 90%, respectively), with similar distribution, in both patients with lung cancer and controls.
  • The homozygous variant genotypes of MnSOD and catalase were not associated with increased lung cancer risk.
  • The erythrocyte SOD and catalase activity was significantly lower among all patients with lung cancer as a whole compared with controls, irrespective of genotypes.
  • However, patients with adenocarcinoma and non-adenocarcinoma showed differences in SOD and catalase activity among different genotypes in comparison with controls.
  • CONCLUSION: The common Val16Ala MnSOD polymorphism and C-T substitution in the promoter region of the catalase gene do not confer increased or reduced risk of lung cancer in Chinese in Hong Kong.
  • [MeSH-major] Adenocarcinoma / genetics. Asian Continental Ancestry Group / genetics. Catalase / genetics. Genetic Predisposition to Disease / ethnology. Lung Neoplasms / genetics. Polymorphism, Genetic. Superoxide Dismutase / genetics

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17409931.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.11.1.6 / Catalase; EC 1.15.1.1 / Superoxide Dismutase
  •  go-up   go-down


97. O'Dowd C, McRae LA, McMillan DC, Kirk A, Milroy R: Elevated preoperative C-reactive protein predicts poor cancer specific survival in patients undergoing resection for non-small cell lung cancer. J Thorac Oncol; 2010 Jul;5(7):988-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated preoperative C-reactive protein predicts poor cancer specific survival in patients undergoing resection for non-small cell lung cancer.
  • BACKGROUND: Although only the minority of patients with non-small cell lung cancer (NSCLC) are suitable for surgical resection, it offers the best possibility of cure.
  • The majority of patients were older than 60 years (71%), men (57%), underwent a lobectomy (65%), and had tumor, node, metastasis stage I disease (66%).
  • On multivariate analysis, only tumor, node, metastasis stage (hazard ratio 1.88, 95% confidence interval 1.34-2.63, p < 0.001) and preoperative C-reactive protein (hazard ratio 1.67, 95% confidence interval 1.01-2.83, p < 0.05) retained independent significance.
  • CONCLUSION: The results of this study indicate that the presence of a systemic inflammatory response predicts poor outcome in patients who have undergone potentially curative resection for lung cancer.
  • [MeSH-major] C-Reactive Protein / metabolism. Carcinoma, Non-Small-Cell Lung / mortality. Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / mortality. Lung Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / immunology. Adenocarcinoma / mortality. Adenocarcinoma / surgery. Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasms, Squamous Cell / immunology. Neoplasms, Squamous Cell / mortality. Neoplasms, Squamous Cell / surgery. Prospective Studies. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20453690.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9007-41-4 / C-Reactive Protein
  •  go-up   go-down


98. Piantedosi FV, Caputo F, Mazzarella G, Gilli M, Pontillo A, D'Agostino D, Campbell S, Marsico SA, Bianco A: Gemcitabine, ifosfamide and paclitaxel in advanced/metastatic non-small cell lung cancer patients: a phase II study. Cancer Chemother Pharmacol; 2008 Apr;61(5):803-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine, ifosfamide and paclitaxel in advanced/metastatic non-small cell lung cancer patients: a phase II study.
  • To investigate the activity/toxicity of T 175 mg/m2 on day 1, I 3 g/m2 on day 1 (with Mesna uroprotection) and G 1,000 mg/m2 on day 1-8, every 3 weeks in the treatment of advanced/metastatic NSCLC, 46 patients (38 male, 8 female) with NSCLC were enrolled: mean age 58 (range 33-70); Stage IIIB/IV=15/31; ECOG PS 0-1/2=31/15; HISTOLOGY: adenocarcinoma=20, squamous=14, large cell=3, NSCLC=8, adenosquamous=1.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17639396.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; P88XT4IS4D / Paclitaxel; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


99. Ikeda N, Hayashi A, Iwasaki K, Kajiwara N, Uchida O, Kato H: Surgical strategy for non-small cell lung cancer in octogenarians. Respirology; 2007 Sep;12(5):712-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical strategy for non-small cell lung cancer in octogenarians.
  • BACKGROUND AND OBJECTIVES: This study was conducted to determine the optimal surgical strategy for octogenarians with non-small cell lung cancer.
  • METHODS: An observational study of 73 patients aged 80 years and over who underwent surgery for non-small cell lung cancer.
  • Cancer types included adenocarcinoma (n = 46), squamous cell carcinoma (n = 22) and large cell carcinoma (n = 5).
  • The 5-year survival rate was 57.4% in pathological stage I, 88.9% in stage II and 18.2% in stage III, respectively.
  • The 5-year survival rate of patients with stage I disease treated by limited resection (58.8%) was similar to that of patients treated by lobectomy (54.9%).
  • Limited resection for stage IA showed slightly better survival than lobectomy (69.4% vs 48.2%, P = 0.10), however, lobectomy was superior to limited resection for stage IB (63.2% vs 16.7%, P = 0.07).
  • CONCLUSION: The early detection of the disease, hopefully in stage IA enables surgical treatment by limited resection of patients aged 80 years and over.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / surgery. Aged, 80 and over. Carcinoma, Large Cell / mortality. Carcinoma, Large Cell / surgery. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / surgery. Female. Humans. Male. Pneumonectomy. Survival Analysis


100. Kim YT, Kim TY, Lee DS, Park SJ, Park JY, Seo SJ, Choi HS, Kang HJ, Hahn S, Kang CH, Sung SW, Kim JH: Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung. Lung Cancer; 2008 Jan;59(1):111-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung.
  • Recent studies have reported that clinical response to epidermal growth factor receptor (EGFR) inhibitors is associated with somatic changes of EGFR in the advanced stage of lung cancer.
  • However, there is no clear data demonstrating whether such molecular changes of EGFR per se can affect the clinical outcome of early stage cancer after surgical resection.
  • DNA mutations of EGFR and KRAS were investigated in 71 adenocarcinoma patients who received surgical resection.
  • However, the EGFR mutation was not associated with age, gender, or clinical stage.
  • The amplification of EGFR copy was frequently observed in the female gender (12/29 (41.4%):3/19 (15.8%); p=0.061) and in the advanced stage (> or =Stage IIIA, 9/19 (47.4%):6/29 (20.7%); p=0.051).
  • KRAS mutations (p=0.000), male gender (p=0.001), absence of BAC feature (p=0.003), advanced stage (p=0.039), and smoking history (p=0.030) were poor prognostic factors for overall survival, whereas EGFR mutation (p=0.184) and amplification (p=0.756) were not.
  • The presence of EGFR mutation was not a prognostic factor of the clinical outcome of early lung cancer after surgical resection.
  • This result provides an important message for the protocol design of future trials of EGFR inhibitors in early lung cancer.
  • DNA mutations of EGFR and KRAS were investigated in 71 adenocarcinoma patients who received surgical resection.
  • Whereas KRAS mutation was a poor prognostic factor, EGFR mutation was not, and its presence per se did not affect the clinical outcome of early lung cancer after surgical resection.
  • [MeSH-major] Adenocarcinoma / genetics. Genes, ras. Lung Neoplasms / genetics. Mutation. Receptor, Epidermal Growth Factor / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17904685.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down






Advertisement